Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults by Machmutow, Katja et al.








Comparative effectiveness of continuation and maintenance treatments for
persistent depressive disorder in adults
Machmutow, Katja ; Meister, R ; Jansen, A ; Kriston, L ; Watzke, Birgit ; Härter, M ; Liebherz, Sarah
Abstract: Background: Persistent depressive disorder (PDD) is defined as a depressive disorder with a
minimum illness duration of two years, including four diagnostic subgroups (dysthymia, chronic major
depression, recurrent major depression with incomplete remission between episodes, and double depres-
sion). Persistent forms of depression represent a substantial proportion of depressive disorders, with
a lifetime prevalence ranging from 3% to 6% in the Western world. Growing evidence indicates that
PDD responds well to several acute interventions, such as combined psychological and pharmacological
treatments. Yet, given the high rates of relapse and recurrences of depression following response to acute
treatment, long-term continuation and maintenance therapy are of great importance. To date, there
has been no evidence synthesis available on continuation and maintenance treatments of PDDs. Objec-
tives: To assess the effects of pharmacological and psychological (either alone or combined) continuation
and maintenance treatments for persistent depressive disorder, in comparison with each other, placebo
(drug/attention placebo/non-specific treatment control), and treatment as usual (TAU). Continuation
treatments are defined as treatments given to currently remitted people (remission is defined as depres-
sive symptoms dropping below case level) or to people who previously responded to an antidepressant
treatment. Maintenance therapy is given during recovery (which is defined as remission lasting longer
than six months). Search methods: We searched Ovid MEDLINE (1950- ), Embase (1974- ), PsycINFO
(1967- ) and the Cochrane Central Register of Controlled Trials (CENTRAL) to 28 September 2018.
An earlier search of these databases was also conducted for RCTs via the Cochrane Common Mental
Disorders Controlled Trial Register (CCMD-CTR) (all years to 11 Dec 2015). In addition we searched
grey literature resources as well as the international trial registers ClinicalTrials.gov and ICTRP to 28
September 2018. We screened reference lists of included studies and contacted the first author of all in-
cluded studies. Selection criteria: We included randomized (RCTs) and non-randomized controlled trials
(NRCTs) in adults with formally diagnosed PDD, receiving pharmacological, psychological, or combined
continuation and maintenance interventions.
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A B S T R A C T
Background
Persistent depressive disorder (PDD) is defined as a depressive disorder with a minimum illness duration of two years, including four
diagnostic subgroups (dysthymia, chronic major depression, recurrent major depression with incomplete remission between episodes,
and double depression). Persistent forms of depression represent a substantial proportion of depressive disorders, with a lifetime
prevalence ranging from 3% to 6% in the Western world. Growing evidence indicates that PDD responds well to several acute interventions,
such as combined psychological and pharmacological treatments. Yet, given the high rates of relapse and recurrences of depression
following response to acute treatment, long-term continuation and maintenance therapy are of great importance. To date, there has been
no evidence synthesis available on continuation and maintenance treatments of PDDs.
Objectives
To assess the effects of pharmacological and psychological (either alone or combined) continuation and maintenance treatments for
persistent depressive disorder, in comparison with each other, placebo (drug/attention placebo/non-specific treatment control), and
treatment as usual (TAU). Continuation treatments are defined as treatments given to currently remitted people (remission is defined as
depressive symptoms dropping below case level) or to people who previously responded to an antidepressant treatment. Maintenance
therapy is given during recovery (which is defined as remission lasting longer than six months).
Search methods
We searched Ovid MEDLINE (1950- ), Embase (1974- ), PsycINFO (1967- ) and the Cochrane Central Register of Controlled Trials (CENTRAL)
to 28 September 2018. An earlier search of these databases was also conducted for RCTs via the Cochrane Common Mental Disorders
Controlled Trial Register (CCMD-CTR) (all years to 11 Dec 2015). In addition we searched grey literature resources as well as the international
trial registers ClinicalTrials.gov and ICTRP to 28 September 2018. We screened reference lists of included studies and contacted the first
author of all included studies.
Selection criteria
We included randomized (RCTs) and non-randomized controlled trials (NRCTs) in adults with formally diagnosed PDD, receiving
pharmacological, psychological, or combined continuation and maintenance interventions.
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Data collection and analysis
Two review authors independently selected studies and extracted and analyzed data. The primary efficacy outcome was relapse/
recurrence rate of depression. The primary acceptance outcome was dropout due to any reason other than relapse/recurrence. We
performed random-effects meta-analyses using risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous
outcomes, with 95% confidence intervals (CI).
Main results
We included 10 studies (seven RCTs, three NRCTs) involving 840 participants in this review, from which five studies investigated
continuation treatments and five studies investigated maintenance treatments. Overall, the included studies were at low-to-moderate risk
of bias. For the three NRCTs, the most common source of risk of bias was selection of reported results. For the seven RCTs, the most common
sources of risk of bias was non-blinding of outcome assessment and other bias (especially conflict of interest due to pharmaceutical
sponsoring).
Pharmacological continuation and maintenance therapies
The most common comparison was antidepressant medication versus tablet placebo (five studies). Participants taking antidepressant
medication were probably less likely to relapse or to experience a recurrent episode compared to participants in the placebo group at
the end of the intervention (13.9% versus 33.8%, RR 0.41, 95% CI 0.21 to 0.79; participants = 383; studies = 4; I2 = 54%, moderate quality
evidence). Overall dropout rates may be similar between participants in the medication and placebo group (23.0% versus 25.5%, RR 0.90,
95% CI 0.39 to 2.11; RCTs = 4; participants = 386; I2 = 64%, low quality evidence). However, sensitivity analyses showed that the primary
outcome (rate of relapse/recurrence) showed no evidence of a difference between groups when only including studies with low risk of bias.
None of the studies compared pharmacological or psychological treatments versus TAU.
Psychological continuation and maintenance therapies
One study compared psychological therapies versus attention placebo/non-specific control. One study compared psychotherapy with
medication. The results of the studies including psychotherapy might indicate that continued or maintained psychotherapy could be a
useful intervention compared to no treatment or antidepressant medication. However, the body of evidence for these comparisons was
too small and uncertain to draw any high quality conclusions.
Combined psychological and pharmacological continuation and maintenance therapies
Three studies compared combined psychological and pharmacological therapies with pharmacological therapies alone. One study
compared combined psychological and pharmacological therapies with psychotherapeutic therapies alone. However, the body of
evidence for these comparisons was too small and uncertain to draw any high quality conclusions
Comparison of different antidepressant medications
Two studies reported data on the direct comparison of two antidepressants. However, the body of evidence for this comparison was too
small and uncertain to draw any high quality conclusions.
Authors' conclusions
Currently, it is uncertain whether continued or maintained pharmacotherapy (or both) with the reviewed antidepressant agents is a robust
treatment for preventing relapse and recurrence in people with PDD, due to moderate or high risk of bias as well as clinical heterogeneity
in the analyzed studies.
For all other comparisons, the body of evidence was too small to draw any final conclusions, although continued or maintained
psychotherapy might be effective compared to no treatment. There is need for more high quality trials of psychological interventions.
Further studies should address health-related quality of life and adverse events more precisely, as well as assessing follow-up data.
P L A I N   L A N G U A G E   S U M M A R Y
Long-term treatment for people with persistent depression
Why is this review important?
Depressive disorders that persist for at least two years cause considerable problems. Even aRer successful treatment, they frequently recur.
Common treatments are antidepressant medicines and psychological treatments (talking therapies), or a combination of both. Long-term
treatments should prevent the recurrence of depressive symptoms.
Who will be interested in this review?
- People with persisting depression (longer than two years), friends, families, and carers.
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)
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- General practitioners, psychiatrists, clinical psychologists, psychological therapists, and pharmacists.
What questions does this review aim to answer?
In adults with persistent depression who improved with acute (short-term) treatment:
- Is receiving continued antidepressant medicine, psychological treatment, or a combination of both more effective in preventing
recurrence of depression compared to placebo (a pretended treatment) or care as usual?
- Is receiving continued antidepressant medicine, psychological treatment, or a combination of both equally accepted as receiving placebo
or usual care?
- Is one treatment more effective or more accepted than another?
Which studies does the review include?
We searched medical databases and other sources to find all relevant studies completed up to September 2018. The studies had to compare
antidepressant treatment, psychological treatment, or a combination of both, with each other, with placebo, or with care as usual for
preventing recurrence of depression in adults diagnosed with persistent depression. We included 10 studies involving 840 participants.
Five studies compared antidepressant medicine with placebo.
One study compared psychological therapies versus attention placebo/non-specific control. One study compared psychotherapy with
medication. Three studies compared combined psychological and pharmacological therapies with pharmacological therapies alone. One
study compared combined psychological and pharmacological therapies with psychotherapeutic therapies alone.
Two studies compared two different antidepressants with each other.
Overall, the included studies were at low-to-moderate risk of bias.
What does the evidence from the review tell us?
According to GRADE, there was moderate quality evidence that participants taking medication treatment probably had less relapses/
recurrences and may have lower dropouts than those taking placebo. The risk of depression returning in participants receiving a placebo
(instead of antidepressant medicine) was 34%. In comparison, participants who remained on antidepressant medicines had a lower risk
for recurrence of 13%. The continued treatment lasted between four months and two years. Antidepressant were as well accepted as
placebo. However, as most of the included studies showed risk of bias and there were some inconsistent results between the different
studies, it cannot be concluded with certainty whether continued or maintained pharmacotherapy (or both) is a convincing treatment for
people with PDD. Additionally, as studies on the long-term effects of medication are lacking, recommendations on the necessary duration
of medication treatment cannot be drawn.
The benefits of psychological therapies or combined treatment remained unclear, due to the small number of studies.
What should happen next?
This review cannot provide clear, certain evidence regarding whether continued antidepressant medication (compared to placebo tablet)
reduces the risk of depression recurring in adults with persistent depression. However, only a few studies have been done. Further studies
should especially address psychological and combined long-term treatments.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.
Pharmacological continuation and maintenance treatment compared with placebo for persistent depressive disorder
Patient or population: people with persistent depressive disorder
Settings: outpatient treatment





























































"Dropout due to any reason" was all reported dropouts due to other reasons
than relapse/recurrence.
1 study only reported dropouts in the first month of the maintenance treat-
ment phase (Kocsis 1996). As the maintenance treatment lasted 24 months, the
dropout rate in this study was very likely to be underestimated.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.




























































































































Very low quality: we are very uncertain about the estimate.
aAssumed risk calculated as the proportion of participants on placebo with the outcome (relapse/recurrence or dropout any) in the four included studies, multiplied by 1000.
bDowngraded due to limitations in the design and implementation of available studies suggesting high likelihood of bias (there were studies with high or unclear risk of bias in
almost all RoB-Domains (except detection bias)).
cDowngraded due to unexplained heterogeneity between studies (I2 = 64%). Due to the small number of included studies, subgroup or meta-regression analyses were not
performed. In two studies, dropout rates were higher in the intervention group, in two studies they were lower.
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B A C K G R O U N D
Description of the condition
Persistent forms of depression that last for two years or
longer represent a substantial proportion of depressive disorders
(Boland 2002; Gilmer 2005; Keller 1992; Spijker 2002). Within the
literature, four subtypes can be distinguished: dysthymia, chronic
major depression, recurrent major depression with incomplete
remission between episodes, and double depression (Dunner
2005). Dysthymic disorder is defined as a condition with mild
depressive symptoms persisting for at least two years. Major
depressive episode (MDD), chronic type, refers to a more severe
condition that meets full criteria for major depression continuously
for a minimum of two years. People who have recovered to the point
at which they no longer meet full criteria for an MDD but continue
to experience significant symptoms for at least two years are
referred to as having recurrent major depression with incomplete
remission between episodes. The superimposition of an MDD on
antecedent dysthymia is referred to as double depression (Klein
2010). In the Diagnostic and Statistical Manual of Mental Disorders
– 5th Edition (DSM-5), the new diagnostic category of persistent
depressive disorder was introduced subsuming dysthymic as well
as chronic major depressive disorders (APA 2013).
The mean length of persistent depression is between 17 and 30
years (Gilmer 2005; Kocsis 2008), and the lifetime prevalence for
persistent depressive disorders is estimated to range from 3% to
6% in the Western world (Kessler 2005; Klein 2010; Murphy 2012).
In comparison to acute forms of depression, persistent depressive
disorders are associated with longer treatment duration; increased
loss of physical wellbeing; increased comorbidity; more severe
impairments in social, psychological, and emotional functioning;
increased healthcare utilization; more frequent suicide attempts;
and more frequent hospitalizations (Arnow 2003; Gilmer 2005).
Thus, persistent depression is likely to make a large contribution
to the high burden of disease that is associated with unipolar
depression according to disability-adjusted life years (WHO 2008).
Description of the intervention
Overall, a large number of different interventions exist
for the treatment of unipolar depression, including
psychological, pharmacological, and combined psychological and
pharmacological therapies. Evidence from randomized controlled
trials (RCTs) as well as meta-analyses suggests that these
interventions are effective in the acute treatment of depression,
including persistent forms of depression (Cuijpers 2010; Cuijpers
2013; Imel 2008; Keller 2000; Kriston 2014; Spijker 2013; von Wolff
2012; von Wolff 2013). Still, there is also evidence that relevant
numbers of people do not respond to treatment, do not reach
complete remission, and develop persisting residual symptoms
long term (Epstein 2014). It is estimated that probably half of people
with depressive disorders develop a chronic course (Klein 2011).
Moreover, acute-phase treatments oRen fail to prevent relapse
(which is defined as the return of symptoms of depression before a
full remission has been achieved) and recurrence (which is defined
as the appearance of another new episode of depression aRer
full remission of a previous episode has been achieved) in major
depression. For example, aRer scheduled termination of acute-
phase cognitive therapy (CT), relapse/recurrence rates were 29%
in the first year and 54% in the second year (Vittengl 2007). In
the same study, even when other depression-specific psychological
therapies and even higher doses of pharmacotherapy were used
aRer the acute-phase treatment, relapse and recurrence rates were
still high (Vittengl 2007). Further, there are studies showing that
30% to 50% of people considered to be remitted still have to deal
with residual depressive symptoms (Nutt 2007).
Thus, following response to acute treatment, long-term
continuation and maintenance therapy might be required
to prevent relapse or recurrence of symptoms. Continuation
treatments are defined as treatments given to currently remitted
people (remission is defined as depressive symptoms dropping
below case level) or to people who previously responded to an
antidepressant treatment. Maintenance therapy is given during
recovery (which is defined as remission lasting longer than
six months; Frank 1991; NICE 2010). The German National
Clinical Practice Guideline for Unipolar Depression recommends
a combination of pharmacotherapy and psychological therapy
as acute-phase treatment for people with persistent forms of
depression (DGPPN 2015). Additionally, a continued psychological
therapy or pharmacotherapy (or both) is recommended to prevent
relapse and recurrence. Specifically, the type of treatment that was
successful in the acute phase is recommended to be continued (APA
2010; DGPPN 2015; NICE 2010). However, the recommendations
concerning the continuation of therapy are based on people
with unipolar depression in general, specific recommendations
regarding people with persistent depressive disorders are lacking.
Hence, a systematic review of evidence regarding the
effectiveness of pharmacological, psychological, and combined
pharmacological and psychological therapies as continuation and
maintenance treatments for people with persistent forms of
depression is needed.
How the intervention might work
Acute treatments aim to reduce depressive symptoms and re-
establish psychosocial functioning. In comparison, continuation
and maintenance treatments aim to maintain (or improve) the
psychofunctional status reached by acute treatment, and to reduce
the likelihood of relapse and recurrence in the long-term (DGPPN
2015). Therefore, continuation and maintenance treatments are
considered to be more than a pure extension of acute treatments,
because continuation/maintenance treatments differ in frequency
and content over the course of the illness in comparison to acute
treatments.
Psychological continuation and maintenance interventions are
usually offered less frequently than acute psychological therapy,
aiming to monitor symptoms and to integrate techniques and
strategies into daily life in the long-term (DGPPN 2015). Different
programmes targeting the prevention of relapse and recurrence
focus on a range of effect mechanisms. CT approaches focus
on the generalization of skills achieved during acute therapy
(Jarrett 1998), or the cognitive content of negative thinking
(Bockting 2005). Mindfulness-based cognitive therapy (MBCT)
was especially developed to reduce relapse and recurrence in
depression (Piet 2011; Segal 2002), and teaches people to deal
with negative feelings and thoughts as a part of their lives through
becoming aware of negative cognitive patterns. Maintenance
interpersonal psychotherapy (IPT) aims to complement skills
gained in the acute-phase therapy and teaches people to
take responsibility in the prevention of future episodes by
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)
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recognizing and preventing stressful environmental and social
circumstances (Beshai 2011). Still, it remains challenging to
completely understand the mechanisms of preventing relapse and
recurrence (Beshai 2011).
The exact therapeutic mechanisms of antidepressants are not yet
clear (Pringle 2011). Most antidepressants seem to increase the
concentrations of monoamine neurotransmitters (e.g. serotonin or
noradrenaline) in the synaptic cleR (Berton 2006). However, the
effect of most antidepressants fully develops aRer some weeks,
indicating that neurophysiological changes of brain tissue (e.g.
changes in sensitivity and frequency of receptors), occurring in the
presence of a constant level of active ingredients, are necessary
for permanent improvement. Depending on the type of active
ingredient, antidepressants can have mood-enhancing, anxiolytic,
or sedative effects and are able to increase or decrease inner drive.
Moreover, the placebo effect is of particular importance in the
treatment of depression. There are studies assuming that the more
severe the depressive symptoms are, the greater the benefit of
antidepressants seem to be compared to placebo (Anderson 2008;
Kirsch 2008). However, one meta-analysis performed on patient-
level data regarding the response to antidepressant medication
showed that initial depression severity and outcomes were
similarly related in treatment and placebo groups (Rabinowitz
2016).
A number of studies have shown that the risk of relapse or
recurrence of depression is associated with residual symptoms
following acute treatment phases (APA 2010; NICE 2010). These
findings lead to the therapeutic goal of sustained remission
and recommendations of international treatment guidelines to
continue antidepressant medication aRer acute-phase treatment
(APA 2010; NICE 2010).
Why it is important to do this review
Research that focuses on the prevention of recurrence of
depression was identified as a top priority in the project
"Depression: asking the right questions" (MQ 2016). The high
prevalence and the severe personal, societal, and economic
consequences of persistent depressive disorder underline the need
for adequate treatment strategies (Gilmer 2005). Growing evidence
indicates that persistent depressive disorder responds well to
several acute interventions, such as combined psychological and
pharmacological treatments, although the number of RCTs is still
limited (Spijker 2013). Yet, given the high rates of relapse and
recurrences of depression following response to acute treatment,
long-term continuation and maintenance therapy are of great
importance (Beshai 2011).
Several RCTs have supported the effectiveness of continuation and
maintenance therapies for depression (Browne 2002; Jarrett 2001;
Jarrett 2013; Keller 2007; Klein 2004; Petersen 2010; Vittengl 2009).
One meta-analysis on relapse prevention with antidepressant
drug treatment of depressive disorders showed that continued
antidepressant medication produced a robust reduction in relapse
(Glue 2010). Another meta-analysis summarized the findings of
long-term effects of cognitive behavioural therapy (CBT) (Vittengl
2007). Participants who responded to acute treatment and
continued to receive CBT showed a significant reduction in relapse
and recurrence rates in comparison to inactive as well as active
controls.
Although most evidence addresses acute treatments for persistent
depressive disorder or long-term treatments for acute depressive
episodes, some studies have addressed the effectiveness of long-
term treatments of persistent depressive disorder (Gelenberg 2003;
Harrison 1986; Keller 1998a; Klein 2004; Kocsis 1996; Kocsis 2003;
Koran 2001; Rouillon 1989; Stangier 2013).
We found no systematic review on the comparative effectiveness
of continuation and maintenance treatments for persistent
depressive disorder.
In summary, this systematic review may be highly relevant as:
• persistent depressive disorders have a high prevalence and
serious personal, societal, and economic consequences;
• no evidence synthesis is available on continuation and
maintenance treatments of persistent depressive disorders;
• high quality evidence synthesis is needed for clinical guideline
recommendations.
O B J E C T I V E S
To assess the effects of pharmacological and psychological
continuation and maintenance treatments for persistent
depressive disorder, in comparison with each other; placebo (drug/
attention placebo/non-specific treatment control); and treatment
as usual (TAU). In addition, to assess the effects of combined
psychological and pharmacological continuation and maintenance
treatments, in comparison with either of these treatments alone.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs), and non-randomized
controlled trials (NRCTs). We considered NRCTs in this review as
we expected a limited number of RCTs. There were no restrictions
regarding other design characteristics. There were no cross-over or
cluster RCTs eligible for inclusion in this review; however, future
versions of this review could consider including these trials.
Types of participants
Characteristics
We included participants aged 18 years or older of any gender and
ethnicity.
Diagnosis
We included participants who had a diagnosis of persistent
depressive disorder or had had this diagnosis before their last
previous acute treatment. The diagnosis of depression needed to
rely on a formal classification system, such as the International
Classification of Diseases (ICD) (WHO 1992), or the Diagnostic
and Statistical Manual of Mental Disorders (DSM) (APA 2013).
Participants needed to be either currently remitted from persistent
depressive disorder or needed to have at least partially responded
to an acute intervention (at least 25% symptom reduction from
baseline) at the beginning of the continuation or maintenance
treatment. We included participants described as 'treatment
resistant' if they fulfilled the formerly mentioned criteria. As the
distinction between subtypes of persistent depressive disorder
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)
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(chronic major depression, dysthymia, double depression, or
recurrent depression without a complete remission between
episodes) is controversial, inclusion was primarily driven by the
duration of the existing depressive disorder. Consequently, we
included studies investigating participants with chronic major
depression, dysthymia, double depression, or recurrent depression
without a complete remission between episodes if the target
disorders were or had been of at least two years' duration. We
excluded studies reporting to investigate 'chronically depressed'
participants without fulfilling these criteria (e.g. less than two years'
duration).
Comorbidities
We included studies that did not define specific concurrent
mental or somatic conditions as inclusion criteria but reported
on comorbidities in addition to the persistent depressive disorder.
We excluded studies focusing exclusively on persistently depressed
participants with a specific concurrent mental or somatic disorder
as we assumed that the interventions in these types of studies
(primarily) addressed the comorbid condition and were not
focused exclusively on persistent depression.
Setting
There were no restrictions based on settings.
Subset data
We only considered studies in which both participants with
persistent and acute forms of depression were included if they
reported data separately for the persistent subgroup (or if 80% or
more of the total sample had a diagnosis of persistent depression).
If randomization was based on the total sample, we included
studies and categorized them as NRCTs.
Types of interventions
Experimental intervention
We considered pharmacological, psychological, and combined
continuation and maintenance interventions. We defined
continuation treatments as treatments given to currently
remitted people or to people who previously responded to
an antidepressant treatment, whereas we defined maintenance
treatments as treatments given to people who were currently
recovered. Continuation/maintenance treatments needed to be
started within one year aRer termination of an acute treatment.
We considered all interventions that satisfied these definitions.
Additionally, we considered studies that did not report all the above
mentioned criteria but reported data on interventions that were
clearly labelled as 'continuation' or 'maintenance' treatments.
We considered pharmacological interventions including the oral
administration of classified antidepressants:
• tricyclic antidepressant (TCA);
• selective serotonin reuptake inhibitor (SSRI);
• monoamine oxidase inhibitor (MAOI);
• alpha2-receptor antagonist;
• selective noradrenaline-dopamine reuptake inhibitor (SNDRI);
• melatonin receptor agonist;
• serotonin 5HT2C receptor antagonist
• noradrenergic and specific serotonergic antidepressants
(NaSSA);
• selective serotonin noradrenaline reuptake inhibitor (SSNRI).
We also considered the following as they can be used (alone or
in combination) in treating different forms of depression (DGPPN
2015):




Psychological therapies had to fulfil the following criteria.
• The intervention must have been based on a scientific
theory (described in detail or manualized or referenced, or a
combination of these).
• At least one contact between therapist and participant either
face-to-face or via telecommunication technologies (e.g. online
therapy) must have taken place. Thus, for example, the general
dissemination of information material in form of leaflets in
waiting rooms was not considered as a psychological therapy.
• The intervention must have considered the personal needs
of the participant or a group of participants and must have
been individually tailored in an interpersonal process. Thus, we
included group therapies.
Concerning psychological therapies, we considered behaviour
therapy/behaviour modification, CBT, third-wave CBTs,
psychodynamic therapies, humanistic therapies, integrative
therapies, systemic therapies, and other psychologically oriented
interventions (based on the definition of the Cochrane Common
Mental Disorders Group) for inclusion.
Combined interventions included the administration of one
or more pharmacological agents combined with one or more
psychological therapy.
Somatic (e.g. electroconvulsive therapy, vagus nerve stimulation,
acupuncture), non-pharmacological (e.g. physical exercise, bright
light therapy), and organizational (e.g. case management)
interventions were not considered as including too many
different interventions was likely to result in large clinical and
methodological heterogeneity.
Comparator intervention
We included both controlled and comparative effectiveness
studies. The comparators were:
• pharmacological placebo (participants received placebo
tablets);
• attention-placebo/non-specific control (participants received a
treatment that involved non-specific psychosocial factors or
assessment only);
• treatment as usual (TAU);
• (other) psychological therapy;
• (other) pharmacological treatment;
• (other) combined psychological/pharmacological therapy.
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Types of outcome measures
Primary outcomes
• Relapse/recurrence rate of depression, preferentially defined as:
* fulfilment of formal diagnostic criteria for depression (DSM,
ICD), or as
* exceeding a cut-off on a depression symptom rating scale
used by the authors, specifically:
□ Hamilton Depression Rating Scale (HAM-D; Hamilton
1960);
□ Montgomery-Åsberg Depression Rating Scale (MADRS;
Montgomery 1979);
□ Beck-Depression-Inventory (BDI; Beck 1996);
□ Inventory of Depressive Symptomatology (IDS; Rush
2000);
□ Patient Health Questionnaire (PHQ; Spitzer 1999); or
□ any other depression symptom scale.
Due to the long tradition of depression research, most instruments
used in clinical trials are usually psychometrically sound. Such
measures were preferred throughout the review (referenced or
sufficient psychometric quality (or both) reported).
• Dropout due to any reason.
Secondary outcomes
• Symptom severity of depression at the end of treatment (metric
outcome of depression scale as defined above).
• Health-related quality of life (e.g. World Health Organization
Quality of Life (WHOQOL) (Skevington 2004).
• Dropout due to any type of adverse event (for the definition of
adverse events see below).
• Any type of adverse event (defined as any potentially negative
event occurring during or aRer treatment in relation to a patient
including symptoms of all body parts (e.g. headache, dizziness,
dry mouth); psychological symptoms (e.g. depressed mood,
suicidal thoughts); and psychosocial, legal, and economic
consequences (e.g. conflicts with the partner, stigmatization)
(Ladwig 2014; Nebeker 2004; Rief 2011).
• Serious adverse events (defined as adverse events leading
to serious consequences such as death, mortal danger,
hospitalization, or disability; FDA 2016). Note that adverse
events need to be differentiated from side effects that are
defined as any adverse event that can be attributed to a lege artis
intervention.
Timing of outcome assessment
The primary outcome time point was the 'end of the
intervention' (regardless of the duration of the intervention).
Additionally, we planned to analyze data at 'one year aRer the end
of the intervention' providing that enough data were available.
If one-year-data were not available, we planned to use data that
ranged between six and 18 months aRer the end of the intervention
with a preference for the time that was closest to one year aRer the
end of the intervention. However, only one study provided follow-
up data 12 weeks aRer the end of the intervention.
Hierarchy of outcome measures
If more than one diagnostic definition or depression symptom
rating scale (or both) was available (concerning relapse or
recurrence rate of depression), we used the presented hierarchy
to select measures (priority starting with: fulfilment of formal
diagnostic criteria, continuing with HAM-D, MADRS, etc.).
Search methods for identification of studies
Electronic searches
Cochrane Common Mental Disorders Controlled Trials Register
(CCMD-CTR)
The Cochrane Common Mental Disorders Group maintains a
specialized register of RCTs, the CCMD-CTR (description in Appendix
1). The Group's Information Specialist ran an initial search of
the CCMD-CTR (11 December 2015) for study records using
the following controlled search terms (condition only): ("chronic
depression" or "dysthymia"or "dysthymic disorder" or "persistent
depressive disorder" or "recurrent depression")
The Information Specialist also searched the CCMD-CTR-references
register (11 December 2015) using a more sensitive set of terms
(condition only): ("chronic* depress*" or "double depress*" or
dysthymi* or (depress* NEAR2 recurr*) or "persistent depressive
disorder"):ti,ab,kw,ky,mh,mc,emt
[Key: ti = title; ab = abstract; kw = keywords; ky = additional
keywords; mh = MeSH terms; mc = MeSH checkwords; emt =
EMTREE terms]
As the scope of this review covers RCTs and NRCTs the information
specialist also ran a scoping search of Ovid PsycINFO (11 December
2015) (Appendix 2). We screened the records retrieved from the
CCMD-CTR and PsycINFO for continuation and maintenance trials,
prior to running all other database searches. The information
specialist used these as a test set to develop the search strategy
further, to prevent the retrieval of too many irrelevant references.
The Information Specialist ran complementary searches on the
following bibliographic databases (September 2016 and 2018)
using relevant subject headings and search syntax, appropriate to
each resource (Appendix 2):
• Cochrane Central Register of Controlled Trials (CENTRAL to Issue
9, 2018);
• Ovid MEDLINE (1946 to 28 September 2018);
• Ovid Embase (1974 to 28 September 2018);
• Ovid PsycINFO (all years to 28 September 2018).
We also searched the international trial registers ClinicalTrials.gov
and ICTRP to 28-09-2018, using the following terms for
ClinicalTrials.gov: (“chronic depression” OR “double depression” OR
dysthymia OR dysthymic OR “recurrent depression” OR “recurrent
depressive disorder” OR “persistent depressive disorder”) AND
(continuation OR maintenance) and the following terms for
ICTRP: chronic depression AND continuation OR double depression
AND continuation OR dysthymia AND continuation OR dysthymic
AND continuation OR recurrent depression AND continuation OR
recurrent depressive disorder AND continuation OR persistent
depressive disorder AND continuation OR chronic depression AND
maintenance OR double depression AND maintenance OR dysthymia
AND maintenance OR dysthymic AND maintenance OR recurrent
depression AND maintenance OR recurrent depressive disorder AND
maintenance OR persistent depressive disorder AND maintenance.
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)









Cochrane Database of Systematic Reviews
There were no restrictions on date, language, or publication status
applied to the searches. The search of the CCMD-CTR was not
repeated in 2018 as it was out of date at the time.
Searching other resources
Grey literature
We searched the following sources of grey literature.
• ProQuest Dissertations and Theses Database
(www.proquest.com/; searched
• 11 August 2015).
• Depression. The Treatment and Management of Depression in
Adults (NICE 2010).
• S3 Guideline/National Disease Management Guideline. Unipolar
Depression (DGPPN 2015).
• Canadian Network for Mood and Anxiety Treatments (CANMAT).
Clinical guidelines for the management of major depressive
disorder in adults (Kennedy 2009).
• Open Grey (www.opengrey.eu/; retrieved 11 August 2015).
As the first search on grey literature revealed no additional results,
we did not repeat it in September 2018, only the main searches (see
above) were updated.
Handsearching
As all relevant journals are included in the bibliographic databases
being searched, we conducted no further handsearches in journals.
Reference lists
We checked the reference lists of all included studies and relevant
systematic reviews to identify additional studies missed from the
original electronic searches (e.g. unpublished or in-press citations).
We also conducted a cited reference search on the Web of Science.
Correspondence
We contacted the first author of all included studies to request
information on unpublished or ongoing studies or additional trial
data.
Data collection and analysis
Selection of studies
Two review authors (KM, SL, RM, or AJ) independently screened
titles and abstracts for inclusion of all the potential studies
identified as a result of the search and coded them as
'retrieve' (eligible or potentially eligible/unclear) or 'do not
retrieve' (ineligible). We retrieved the full-text reports/publications
and two review authors (KM, SL, or RM) independently screened
the full-texts and selected studies for inclusion. We recorded
reasons for exclusion of the ineligible studies. We resolved any
disagreement through discussion or, if required, we consulted a
fourth review author (AJ). We identified and excluded duplicate
records and we collated multiple reports that related to the
same study so that each study, rather than each report, was
the unit of interest in the review. We recorded the selection
process in sufficient detail to complete a PRISMA flow diagram and
Characteristics of included studies and Characteristics of excluded
studies tables.
Data extraction and management
We used a data collection form, which had been piloted on one
study in the review (Klein 2004), to extract study characteristics and
outcome data. Three review authors (KM, SL, RM) extracted data
from this study for piloting the data collection form. Extraction of
the data of the remaining included studies was undertaken by two
review authors (KM, SL, or RM), who independently extracted study
characteristics and data. We extracted the following.
• Methods: study design, time of randomization, total duration of
study, location, study setting, and date of study (year).
• Participants: number of participants (n), mean age, age range,
% women, diagnostic subgroup, mean age of onset, length of
current/last episode, number of previous episodes.
• Interventions: intervention, comparison, type of acute
treatment previous to continuation/maintenance treatment.
• Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
• Notes: funding of the trial.
We noted in the Characteristics of included studies table if outcome
data were not reported in a usable way. We resolved disagreements
by consensus or by involving a third review author (KM, SL, or RM).
One review author (SL) transferred data into Review Manager 5
(Review Manager 2014). We double-checked that data were entered
correctly by comparing the data presented in the systematic review
with the study reports. A second review author (KM) spot-checked
study characteristics for accuracy against the trial report.
Main comparisons
We chose seven main comparisons from the list of possible
comparisons based on clinical importance and expected frequency
of the comparisons in clinical trials:
• pharmacological continuation and maintenance therapies
versus placebo;
• pharmacological continuation and maintenance therapies
versus TAU;
• psychological continuation and maintenance therapies versus
attention placebo/non-specific control;
• psychological continuation and maintenance therapies versus
TAU;
• psychological continuation and maintenance therapies versus
pharmacological continuation and maintenance therapies;
• combined psychological and pharmacological continuation and
maintenance therapies versus pharmacological continuation
and maintenance therapies alone;
• combined psychological and pharmacological continuation and
maintenance therapies versus psychotherapeutic continuation
and maintenance therapies alone.
Assessment of risk of bias in included studies
Two review authors (KM, SL, or RM) independently assessed risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion or by involving
another review author (KM, SL, or RM). We assessed the risk of bias
according to the following domains:
• random sequence generation;
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• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective outcome reporting;
• other bias.
We judged each potential source of bias as high, low, or unclear and
provided a supporting quotation from the study report together
with a justification for our judgement in the 'Risk of bias' table. We
summarized the risk of bias judgements across different studies
for each of the domains listed. Where information on risk of bias
related to unpublished data or correspondence with a trialist, we
noted this in the 'Risk of bias' table.
We used the ROBINS-I tool for assessing the quality of non-
randomized studies in meta-analyses to assess the quality of NRCTs
(Sterne 2016). This tool shows substantial overlap with the risk of
bias ratings in RCTs, but additionally includes two domains at the
preintervention level (bias due to confounding, bias in selection
of participants into the study) and one domain at the intervention
level (bias in classification of interventions).
We included no cluster-randomized trials; however, in updates
of this review we will consider recruitment bias, baseline
imbalance, loss of clusters, incorrect analysis, and comparability
with individually randomized trials in cluster-randomized trials
(Higgins 2011).
We used sensitivity analyses to consider the risk of bias. Moreover,
we took the risk of bias into account when interpreting the
treatment effects.
Measures of treatment effect
Dichotomous data
To increase clinical applicability of the findings, we calculated the
risk ratio (RR) and 95% confidence intervals (CI) of the primary
outcomes relapse/recurrence and dropout due to any reason, as
they are more likely to help clinicians to make informed decisions
in specific clinical situations. For rare outcomes (adverse events)
or endpoints with highly varying baseline rates, we estimated odds
ratios (OR) and 95% CIs. When the overall results were significant,
we calculated the number needed to treat for an additional
beneficial outcome (NNTB). None of the included studies in this
review used time-to-event data, however in future versions of this
review primary studies should consider pooled hazard ratios for
calculations.
Continuous data
We analyzed continuous data as mean differences (MD) and 95%
CIs when studies used the same rating scale. When studies used
different scales, we calculated standardized mean differences
(SMD) and 95% CIs. We entered data presented as a scale with a
consistent direction of effect. We undertook meta-analyses only
where this was meaningful (i.e. if the treatments, participants,
and underlying clinical question were similar enough for useful
pooling). We planned to narratively describe skewed data reported
as medians and interquartile ranges if effect size calculation was
not possible.
Time-to-event data
We planned to consider pooled hazard ratios for calculation of
time-to-event data.
Unit of analysis issues
Cross-over and cluster-randomized trials
As we expected a small number of overall available studies,
data from cross-over trials and cluster-randomized trials were
planned for inclusion in the analysis, regardless of the level of
randomization. None of the studies in this review was either a
cross-over or a cluster-randomized trial. However, in updates of
this review, cluster-randomized trials should include direct effect
estimates of the primary studies, only if they were obtained from
analyses that accounted for the clustering in the data (e.g. using
a multilevel model). Otherwise, the effect estimates should be
approximated using an inflated standard error that incorporates
the design effect (Higgins 2011). For cross-over trials, only the first
comparison (precross-over) meeting our inclusion criteria should
be used.
Studies with multiple treatment groups
For studies with multiple treatment groups, for each of the main
objectives addressed in our review, we considered only data
from the comparison of interest. If the study provided more than
one comparison of interest for one of the main objectives, we
planned to divide the number of participants in the arm used
several times by the number of arms for all analyses to avoid
including participants more than once in the analysis. However, this
procedure was not necessary in our analyses.
Dealing with missing data
In case of missing or unclear data, we contacted corresponding
authors or study sponsors to obtain key study characteristics and
missing numerical outcome data when possible (e.g. when a study
was identified as abstract only). We documented all requests and
correspondence.
For all studies, we planned to calculate effect sizes using the
intention-to-treat (ITT) principle (i.e. analyzing all participants
allocated to the respective study arm). For the primary outcomes,
all randomized participants were included in the analyses (when
possible) irrespective of how the authors of the primary studies
defined their ITT sample. For all other outcomes, we followed the
definition of the ITT sample provided by the authors. Where authors
reported no ITT data, we used the data provided.
Assessment of heterogeneity
We tested statistical heterogeneity between studies for significance
using Cochrane's Q-test and quantified it using the I2 statistic
(Higgins 2003).
Results were visually displayed as forest plots. We expected
considerable clinical heterogeneity between studies. I2 values
in the range of 0% to 40% might not be important, 30%
to 60% may represent moderate heterogeneity, 50% to 90%
may represent substantial heterogeneity, and 75% to 100%
considerable heterogeneity. Based on this classification, we
considered I2 values in the range of 50% to 100% as relevant
statistical heterogeneity that was to be further explored. As
"thresholds for the interpretation of I2 can be misleading, since the
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importance of inconsistency depends on several factors" (Higgins
2011), this was only a rough orientation. Therefore, we decided on
a case-by-case-basis if the determined heterogeneity needed to be
further explored.
Assessment of reporting biases
We tested for possible reporting biases and small-study effects
using visual examination of funnel plots (when useful). We planned
to use Egger's test for test of publication bias, requiring a minimum
of 10 studies per comparison (Sterne 2001).
Data synthesis
All analyses used a random-effects model (DerSimonian 1986).
We used a random-effects rather than fixed-effect model because
we assumed that the included studies would not be functionally
equivalent and would show considerable clinical (concerning
population, intervention) and methodological (concerning quality)
heterogeneity. Results are visually displayed as forest plots.
If it was not possible to combine studies via meta-analysis, we
provided a narrative summary.
Subgroup analysis and investigation of heterogeneity
To identify possible treatment effect moderators, we planned a
priori defined subgroup analyses (in case of categorical predictors)
or meta-regression analyses (in case of metric predictors) for the
primary outcomes.
We considered the following variables in subgroup analyses:
• subtype of persistent depressive disorder (dysthymia versus
other): a possibly moderating effect of subtype would suggest
that a distinction between these subtypes might be used for
allocation of people to treatments (differential indication). In
contrast, a possible homogeneity of effects across subtypes may
suggest that a distinction is of little relevance in the day-to-day
practice. We planned to test dysthymia against other subtypes
as dysthymia is assumed to be the most frequently mentioned
subtype;
• mean age of onset: the age of onset is known as a relevant
predictor, it should be assessed if people with early onset need
different treatments;
• applied intervention (CBTs versus other, SSRIs versus other):
experience shows that CBT approaches/SSRIs are the most
frequent forms of psychological therapies/antidepressants to be
studied. Therefore, we decided to test these approaches versus
other approaches. Evidence on the best available treatments (in
case of considerable differences) is indispensable for guideline
recommendations;
• duration of continuation/maintenance treatment (weeks):
for guideline recommendations and clinical practice, it is
indispensable to know if different treatment durations result
in different outcomes, e.g. if longer treatments lead to better
outcomes.
In case of considerable heterogeneity between study results that
could not be explained by the a priori defined subgroup and
meta-regression analyses, we planned to perform a series of
a posteriori (explorative) meta-regression analyses to identify
sources of heterogeneity. A priori and a posteriori analyses should
be clearly labelled as such.
Sensitivity analysis
We performed sensitivity analyses excluding studies with a high
or unclear risk of bias (separately for each of the seven domains
according to Cochrane's 'Risk of bias' tool, when possible) or
outlying findings (or both). Results were contrasted to those
acquired with data from all studies to control for possible effects of
study quality on pooled effects.
We planned additional sensitivity analysis: excluding trials without
a randomization on person level (second phases of cross-over
trials, NRCTs, and cluster-randomized trials) and excluding trials
without (re)randomization immediately before the continuation/
maintenance phase to control for possible design effects.
'Summary of findings' table
We included the comparison of effectiveness of pharmacotherapy
versus placebo for persistent depressive disorder in Summary of
findings for the main comparison. 'Summary of findings' tables
include a summary of the quality of evidence, the magnitude of
effects of the according intervention and a summary of available
data on the primary outcomes (relapse/recurrence and dropout
due to any reason). We expressed findings as measures of RR and
absolute risk, with 95% CIs and used the GRADE approach to assess
the quality of the body of evidence (Guyatt 2011).
R E S U L T S
Description of studies
Results of the search
The CCMD Information Specialist conducted initial searches in
December 2015 of the CCMD-CTR (studies and references registers)
and Ovid PsycINFO, retrieving a total of 4489 records. In September
2016, aRer we had screened the initial search results the
Information Specialist ran further searches of CENTRAL and a
cross-search of Ovid MEDLINE, Embase and PsycINFO, retrieving an
additional 929 records (aRer exclusion of duplicates). In October
2016, we searched and screened several sources of grey literature,
reference lists of relevant systematic reviews and studies, and
correspondended with authors of included studies to date, which
yielded an additional 834 records. ARer removal of duplicates, two
review authors (SL, KM, RM, or AJ) independently screened all 5520
records by title and abstract and excluded 5000 records as they did
not meet our inclusion criteria. Two out of three review authors
(SL, KM, or RM) independently checked each of the remaining
520 full-text reports for eligibility. We included 17 publications
(representing 10 studies) for the qualitative synthesis, and out of
this pool we used 10 publications for the quantitative synthesis.
One additional study is classified as 'awaiting classification', as the
recruiting process has not finished yet (NCT03219879). The PRISMA
flow diagram displays the details of the selection process (see
Figure 1).
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Figure 1.   Study flow diagram. NRCT: non-randomized controlled trial; PDD: persistent depressive disorder; RCT:
randomized controlled trial.
 
In September 2018, the Information Specialist repeated the
searches of Ovid MEDLINE, Embase, PsycINFO together with
a search of the Cochrane Library trials database (CENTRAL).
The update search retrieved 141 additional records (aRer de-
duplication). We screened these 141 records and identified 20
records for which we did a full-text screening. Only one study
fulfilled the inclusion criteria, but this study was already included
in the systematic review (duplicate).
We also repeated the searches in the WHO International
ClinicalTrials Registry Platform (ICTRP) and ClinicalTrials.gov (to
September 2018) and identified 232 new records. Of these 232
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records, 231 were excluded and one is a duplicate (classified as
'awaiting classification', see above).
Included studies
We included 17 publications, describing 10 studies: five
continuation and five maintenance studies. In Table 1, column
'Study ID', we mentioned the 10 main publications. Three
further publications described the acute phases of the included
continuation and maintenance studies (Keller 1998a; Keller 2000;
Marin 1994; see Table 1, column 'Related acute-phase study'),
one publication was a study protocol (Rush 1998), and three
publications (Berndt 2000; Kocsis 1997; Kocsis 2002) provided
additional analyses on the studies of Keller 1998b and Koran 2001.
Thus, these seven publications provided information missing in
the 10 main publications (e.g. location of the study, comorbidities,
detailed information on the interventions).
There were partially overlapping participant groups between
the different continuation/maintenance treatment studies that
followed one acute treatment study. However, these studies
focused on different comparisons and were not included in
the same analyses. Two exceptions were the studies of Kocsis
1996 and Miller 2001. These two studies focused on the same
comparison (desipramine versus placebo) during the maintenance
phase, but analyzed different diagnostic subgroups. While Miller
2001 analyzed solely participants with dysthymia, Kocsis 1996
included participants with a chronic MDD and double depression.
Both studies shared the group of participants with dysthymia,
although just partially as Miller 2001 also included participants with
dysthymia not involved in Kocsis 1996.
Two studies investigated solely continuation treatments (Harrison
1986; Hellerstein 2001). The other eight studies followed three
acute treatment studies, and investigated both continuation and
maintenance treatments (Gelenberg 2003; Keller 1998b; Klein 2004;
Kocsis 1995; Kocsis 2003; Koran 2001; Miller 2001).
Comparisons
We predefined seven relevant comparisons.
1. Pharmacological continuation and maintenance therapies versus
placebo
Five of 10 studies included comparisons of an antidepressant
medication with a pharmacological placebo (Gelenberg 2003;
Harrison 1986; Keller 1998b; Kocsis 1996; Miller 2001). Two of
these five studies compared desipramine versus placebo in the
maintenance phase, but used different subgroups for analyses (see
Table 1) (Kocsis 1996; Miller 2001).
2. Pharmacological continuation and maintenance therapies versus
treatment as usual
There were no studies comparing pharmacological therapies
versus TAU.
3. Psychological continuation and maintenance therapies versus
attention placebo/non-specific control
One study compared psychotherapy versus assessment only (Klein
2004).
4. Psychological continuation and maintenance therapies versus
treatment as usual
There were no studies comparing psychological therapies versus
TAU.
5. Psychological continuation and maintenance therapies versus
pharmacological continuation and maintenance therapies
One study with three treatment arms compared pharmacological,
psychological, and combined continuation therapy (Kocsis 2003).
6. Combined psychological and pharmacological continuation and
maintenance therapies versus pharmacological continuation and
maintenance therapies alone
Two studies compared combined psychological and
pharmacological continuation and maintenance therapies versus
pharmacological continuation and maintenance therapies alone
(Hellerstein 2001; Kocsis 2003 with three treatment arms
(pharmacological, psychological, and combined continuation
therapy)).
7. Combined psychological and pharmacological continuation and
maintenance therapies versus psychotherapeutic continuation and
maintenance therapies alone
One study compared combined psychological and
pharmacological continuation and maintenance therapies versus
psychotherapeutic continuation and maintenance therapies alone
(Kocsis 2003 with three treatment arms (pharmacological,
psychological, and combined continuation therapy)).
We included one a posteriori comparison.
8. Pharmacological continuation and maintenance therapies versus
other pharmacological continuation and maintenance therapies (post
hoc)
Two studies compared pharmacological continuation and
maintenance therapies versus other pharmacological continuation
and maintenance therapies (post hoc) (Kocsis 1995; Koran 2001).
Design
Two studies used a randomized, controlled, parallel-group design
to investigate the continuation treatment phase (Harrison 1986;
Hellerstein 2001). Three studies investigated a continuation
treatment within an NRCT, that is, the participants continued
to receive the same treatment that was effective during acute
treatment (Kocsis 1995; Kocsis 2003; Koran 2001). Each of these
three studies was followed by maintenance treatments applying
a randomized, controlled, parallel-group design (Gelenberg 2003;
Keller 1998b; Klein 2004; Kocsis 1996; Miller 2001). Continuation
treatments lasted between 16 and 26 weeks, maintenance
treatments between 52 and 104 weeks. All 10 studies involved
preceded acute treatments in their study design (see Table 1).
Sample size
Study size varied widely. The two studies investigating solely
a continuation treatment randomized 12 participants (Harrison
1986) and 40 participants (Hellerstein 2001). Two studies
randomized 329 participants (Kocsis 2003) and 386 participants
(Koran 2001) for the continuation phase and rerandomized 82
participants (Klein 2004) and 161 participants (Keller 1998b)
for the subsequent maintenance phase. Another study (Kocsis
1995) randomized 73 participants to the continuation phase
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and rerandomized between 27 participants (Miller 2001) and 53
participants (Kocsis 1996) to the subsequent maintenance phase.
Setting
Two studies were multicentre (Harrison 1986; Hellerstein 2001), and
five were single centre (Gelenberg 2003; Keller 1998b; Klein 2004;
Kocsis 2003; Koran 2001). One study was conducted multicentre
during the continuation treatment (Kocsis 1995), and continued
single centre during the maintenance phase (Kocsis 1996; Miller
2001). All studies were conducted in the US and used an outpatient
setting for treatment.
Inclusion criteria
All studies required the participants to meet DSM criteria
for persistent depressive disorder by the time of entering
the study (i.e. start of acute treatment). Two continuation
treatment studies included people with dysthymia (Harrison 1986;
Hellerstein 2001), whereby the latter one focused on people
with early-onset dysthymia. While Koran 2001 and Keller 1998b
included participants with either a chronic depressive episode
or double depression, Gelenberg 2003, Kocsis 2003, and Klein
2004 additionally included participants with recurrent depression
with incomplete interepisode remission. Kocsis 1995 analyzed
participants with either dysthymia or double depression in the
continuation treatment phase. The subsequent maintenance
treatment phase included participants with either chronic major
depressive disorder, dysthymia, or double depression, whereby
Miller 2001 analyzed only people with dysthymia.
All studies used explicit response or remission criteria for entry into
continuation or maintenance phases. Participants were required to
show at least clinical response or partial remission, scoring below
15 on the HAM-D (Gelenberg 2003; Klein 2004; Kocsis 2003), or to
range between a score of 11 and 12 on the HAM-D (Kocsis 1996;
Miller 2001). Harrison 1986 required the participants to reach a
score of 1 or 2 ("very much improved" or "much improved") on
the Clinical Global Impression (CGI). Keller 1998b and Koran 2001
required participants to fulfil both a HAM-D score of 15 or less and
a CGI score of less than 3 (i.e. no more than mild depression). One
study additionally defined specific remission criteria based on the
Longitudinal Interval Follow-up Evaluation (LIFE) for participants
with double depression (Koran 2001), scoring 1 (no symptoms) or
2 (some symptoms) during four weeks. Compared to acute-phase
baseline scores, six studies determined response or remission
with at least 50% decrease of symptoms (Gelenberg 2003; Keller
1998b; Klein 2004; Kocsis 2003; Koran 2001; Miller 2001), and one
study with at least 40% reduction of symptoms (Hellerstein 2001).
For the studies investigating continuation treatments, participants
had to achieve the defined response or remission criteria directly
at the end of acute treatment (Hellerstein 2001; Kocsis 2003),
or had to maintain the specific score for the last four weeks
before entering the continuation phase (Koran 2001). For the
studies investigating maintenance treatments, participants had
to continue their response or remission throughout the end of
continuation treatment for being eligible to enter the maintenance
phase (Gelenberg 2003; Keller 1998b; Klein 2004; Kocsis 1996; Miller
2001). Participants included in the studies had to be aged between
21 and 65 years (Hellerstein 2001; Keller 1998b; Koran 2001) or
between 18 and 75 years (Gelenberg 2003; Klein 2004; Kocsis 2003).
Exclusion criteria
Five studies described criteria for excluding participants prior
to study entry (i.e. before starting the acute treatment of the
study programme). Six studies excluded participants who failed
to respond to either at least one adequate trial of antidepressant
medication (Harrison 1986; Keller 1998b; Koran 2001) or who failed
to respond to three or more previous trials of antidepressant
medication or at least two trials of empirical supported
psychotherapy, or both (Gelenberg 2003; Klein 2004; Kocsis
2003). Nine studies (except Harrison 1986) excluded participants
with serious medical illness, DSM diagnosed axis I disorders (if
principal), personality disorders, present psychotic symptoms, or
immediate suicidal risk. Five studies excluded participants who
took concomitant (psychoactive) medication or who had received
electroconvulsive therapy either within three months (Keller 1998b;
Koran 2001) or three years prior to study entry (Gelenberg 2003;
Klein 2004; Kocsis 2003). Hellerstein 2001 excluded participants
who underwent another parallel psychotherapy, and Koran 2001
and Keller 1998b excluded participants who started another
psychotherapy within the previous three months before entering
study.
Participant characteristics
While one study reported that the majority of included participants
were aged in their 30s or 40s (Harrison 1986), all other studies
provided mean age scores of participants varying between 36
and 45 years. Harrison 1986 included predominantly women
(83%), while the proportion of women varied between 50% and
66% in all other studies. Distribution of diagnostic subgroups
differed among the included studies, whereby eight studies
treated participants of several diagnostic subgroups, and two
studies analyzed solely people with dysthymia (Hellerstein 2001;
Miller 2001). The number of participants with double depression
varied between 23% and 63% (Gelenberg 2003; Harrison 1986;
Keller 1998b; Klein 2004; Kocsis 1995; Kocsis 1996; Kocsis 2003;
Koran 2001). Six studies treated participants with a chronic
depressive episode (Gelenberg 2003; Keller 1998b; Klein 2004;
Kocsis 1996; Kocsis 2003; Koran 2001), of which the amount varied
between 11% and 55%. Three studies also treated participants
diagnosed with a recurrent depressive episode with incomplete
interepisode remission (Gelenberg 2003; Klein 2004; Kocsis 2003);
the amount varied between 22% and 29%. Three studies also
treated participants with dysthymia, of which the amount varied
between 37% and 40% (Harrison 1986; Kocsis 1995; Kocsis 1996).
Although other axis I disorders (if principal) and personality
disorders were an exclusion criterion in almost all studies,
some studies described percentages of single comorbid mental
conditions with the following percentages:
• Keller 1998b: 26% anxiety disorders, 37% substance abuse, 30%
alcohol abuse, 48% axis II disorders;
• Klein 2004: 27% anxiety disorders, 26% substance abuse;
• Kocsis 2003: 31% anxiety disorders, 29% alcohol abuse;
• Kocsis 1996: 34% anxiety disorders, 48% axis II disorders.
As only serious medical illnesses were an exclusion criterion,
participants could have more harmless illnesses. However, none
of the included studies reported data on comorbid somatic
conditions.
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Six studies provided data on the mean age of onset, which ranged
from 12.3 to 29.5 years. The mean length of the current/previous
episode was 73.2 to 105.6 months (data provided in five studies:
Gelenberg 2003; Keller 1998b; Klein 2004; Kocsis 2003; Koran 2001).
Four studies provided data on the number of previous episodes and
reported a mean number of 1.3 to 3.0 episodes (Hellerstein 2001;
Keller 1998b; Klein 2004; Koran 2001). Three studies reported the
mean lifetime duration of the depressive disorder (Harrison 1986:
15.0 years; Koran 2001: 16.6 years; Miller 2001: 24.0 years).
Four studies reported data on previous medications (Keller
1998b; Kocsis 1996; Kocsis 2003; Miller 2001), the percentages of
participants previously received antidepressants ranged from 22%
(Keller 1998b) to 57% (Kocsis 2003).
Five studies reported data on previously received psychotherapy
(Hellerstein 2001; Keller 1998b; Kocsis 2003; Miller 2001); this
applied to 63% (Keller 1998b) to 85% (Miller 2001) of the included
participants.
Types of intervention
Antidepressant drugs and drug placebo interventions
Continuation treatment: one continuation treatment study
compared an active antidepressant drug with a tablet placebo
(Harrison 1986). This study used the MAOIs phenelzine as active
treatment for 26 weeks. Participants in the active group received on
average phenelzine 51 mg daily. Participants in the placebo group
discontinued phenelzine treatment over a period of 14 days by
reducing the daily dose by 15 mg every two to three days. Two
continuation treatment studies included a direct comparison of
two antidepressant medications. Koran 2001 compared sertraline
(SSRI) 50 mg to 200 mg per day to imipramine (TCA) 50 mg to 300
mg per day for 16 weeks. The dose could be adapted by 50 mg
per day each week depending on the participant's symptoms and
adverse effects. The second study compared two TCAs during 16 to
20 weeks of treatment (Kocsis 1995). Participants received the same
final dose achieved during acute treatment (imipramine 300 mg per
day or desipramine 200 mg per day). Two continuation treatment
studies included comparisons of antidepressant medication alone
versus medication plus psychotherapy. Kocsis 2003 investigated
three active treatment arms, including nefazodone (SNDRI) alone,
psychotherapy alone (Cognitive Behavioral Analysis System of
Psychotherapy), and nefazodone plus psychotherapy over 16
weeks. In both medication arms, participants received nefazodone
300 mg per day to 600 mg per day. Hellerstein 2001 compared
fluoxetine (SSRI) alone with fluoxetine plus group psychotherapy
over 16 weeks. Participants in both arms received fluoxetine 20 mg
per day to 80 mg per day.
Maintenance treatment: four maintenance treatment studies
included the comparison of an active antidepressant drug with
a tablet placebo (Gelenberg 2003; Keller 1998b; Kocsis 1996;
Miller 2001). Of these four, two studies analyzed the same
comparison (desipramine versus placebo) but with focus on
different diagnostic subgroups (Kocsis 1996; Miller 2001). In Keller
1998b, the participants in the active treatment group received
a flexible daily dose of sertraline hydrochloride 50 mg to 200
mg (SSRI) for 76 weeks. Participants in the placebo arm reduced
the sertraline dose by 50 mg every week and received placebo
substitution. Gelenberg 2003 used nefazodone SNDRI at the same
dose being effective during the previous continuation phase (300
mg per day and 600 mg per day) over 52 weeks. Participants in
the placebo arm received identical (but inactive) tablets without
any stepwise reduction between continuation and maintenance
phase. Kocsis 1996 and Miller 2001 used desipramine (TCA) over
104 weeks as maintenance treatment. Participants in the active
group maintained the dose (75mg per day to 350 mg per day) of
the previous continuation phase. Participants in the placebo arm
reduced their dose by 25% per week during the first month of
maintenance treatment and subsequently started a treatment with
identical placebo tablets.
Types of psychological therapies
Three studies investigated psychotherapeutic treatments, two
continuation treatment studies and one maintenance treatment
study.
Kocsis 2003 examined the Cognitive Behavioral Analysis System
of Psychotherapy (CBASP; McCullough 2000) during the 16-
week continuation phase. Participants received six sessions
of manualized CBASP, both in the CBASP and the combined
treatment arm. The continuation treatment study of Hellerstein
2001 compared fluoxetine (SSRI) alone with a group receiving
fluoxetine plus manualized group psychotherapy in a 16-week
continuation phase. The combined group received treatment
according to an unpublished manual of Cognitive-Interpersonal
Group Psychotherapy for Chronic Depression (CIGP-CD), combining
cognitive and interpersonal approaches. Up to 10 participants
formed a group with weekly meetings of 90 minutes.
Klein 2004 investigated CBASP versus assessment only in a 52-
week maintenance phase which followed the study of Kocsis
2003 (see above). Participants in the CBASP group received one
session every four weeks for up to 13 sessions, and were evaluated
by an independent evaluator every four weeks. Participants in
the assessment only group met the project co-ordinator and the
independent evaluator also every four weeks, hence received some
attention but no active treatment.
Process evaluation of psychological treatments
One continuation treatment study (Hellerstein 2001) and one
maintenance treatment study (Klein 2004) provided information on
process evaluation.
Hellerstein 2001 involved two clinical psychology PhD students
with extensive psychotherapy training for conducting the group
therapy in the continuation treatment phase. On a weekly basis,
these two students met a senior psychiatrist supervisor for two
months for reviewing how to conduct the treatment with the CIGP-
CD treatment manual. By the start of the study treatment, sessions
with the participants were audiotaped and supervised weekly for
adherence to the manual.
Information on the CBASP sessions in the maintenance treatment
study was inferable from the main publication (Klein 2004).
There was additional information from the publication of the
acute treatment phase (Keller 2000). The CBASP sessions were
all videotaped and conducted by psychotherapists with at least
two or five years of experience (dependent on last degree
achieved). The therapists underwent a two-day training workshop
with James P McCullough (founder of CBASP) including an
evaluation of two videotaped pilot cases before starting treatment
with study participants. Throughout the maintenance phase, the
designated supervisors at each site assessed therapist's adherence
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to treatment procedures biweekly by reviewing videotapes. These
supervisors were directly supervised by James P McCullough.
Treatment adherence was measured using a CBASP-specific rating
scale developed by McCullough (McCullough 2000). In case of non-
adherence, an immediate meeting with the respective therapist
was scheduled and opportunities for improvement were discussed.
Types of outcome measures
Primary outcomes
The primary efficacy outcome was rates of relapse or recurrence of
depression, defined by exceeding a specific score on the HAM-D or
on the severity of the CGI, by fulfilling DSM criteria for an MDD, by
clinical judgement of the research team during a predefined range
of time, or a combination of these.
Two continuation studies applied criteria for relapse, either scoring
below a satisfactory response during four weeks (Koran 2001), or
scoring three or more on the CGI during two weeks (Harrison 1986).
In the maintenance treatment study of Keller 1998b, participants
had to fulfil DSM criteria for an MDD during three consecutive
weeks, a CGI rating of three or more, and an increase of at least
four points on the HAM-D (compared to maintenance baseline)
to be diagnosed as having a recurrence. One week later, a senior
investigator determined the diagnosis within a clinical interview to
confirm relapse. Two other maintenance treatment studies defined
a participant's recurrence by a score of 12 or more on the HAM-D
and a score below 60 on the GAS on three consecutive ratings within
four weeks (Kocsis 1996; Miller 2001). Also, if a participant fulfilled
these criteria on just one rating but was considered to need urgently
alternative treatment, the participant was rated as being recurred.
One continuation treatment study (Kocsis 2003), and two
maintenance treatment studies (Gelenberg 2003; Klein 2004),
applied the same criteria for recurrence, as they followed the same
acute treatment study (Keller 2000). These three studies required
the participants to score 16 or higher on the HAM-D, to fulfil DSM
criteria for an MDD on two consecutive visits, and to undergo a
clinical interview with a senior investigator confirming recurrence.
They also applied another definition in case a participant scored 16
or more on the HAM-D but did not fulfil MDD criteria or discontinued
before a second visit for clarification. Then, senior investigators
reviewed the data of such participants at the end of the study,
discussed and decided if and at what time an MDD had occurred,
and if the participant could be considered to have recurred.
Two studies did not address relapse or recurrence (Hellerstein 2001;
Kocsis 1995).
The primary safety/acceptability outcome was dropout due to
any reason other than recurrence. Nine studies reported overall
dropout rates. Most of the studies also reported reasons for dropout
(see 'Secondary outcomes' below). One study did not report any
dropouts (Miller 2001).
Secondary outcomes
Metric outcomes of depression severity scales and quality of
life measures were reviewed as secondary efficacy outcomes.
Six studies reported changes in severity of depressive symptoms
from pre- to post-treatment on the HAM-D (Gelenberg 2003;
Harrison 1986; Hellerstein 2001; Keller 1998b; Klein 2004; Koran
2001). Three studies included quality of life measures (Hellerstein
2001; Keller 1998b; Koran 2001). The continuation treatment
study of Koran 2001 reported data on the Quality of Life
Enjoyment and Satisfaction Questionnaire (Q-LES-Q), a self-report
measure obtaining the degree of enjoyment and satisfaction in
different areas of daily functioning. In the subsequent maintenance
treatment study, Keller 1998b used the 36-item Short-Form Health
Survey (SF-36), and reported data on three subscales (social
functioning, role limitations owing to emotional problems, role
limitations owing to physical health problems) in a further
publication (Kocsis 2002). Hellerstein 2001 used the Satisfaction
With Life Scale (SWLS), a self-report measure of subjective life
satisfaction. Only one study reported follow-up outcome data (both
for the HAM-D and the SWLS scores) 12 weeks aRer the end of the
intervention.
Measures of safety (i.e. dropout due to any type of adverse event
and the occurrence of any or severe adverse events) were also
reviewed. Five of 10 studies reported dropout due to adverse
events other than recurrence, and all of these studies compared
antidepressant medication with placebo or another medication
(Gelenberg 2003; Harrison 1986; Keller 1998b; Kocsis 1995; Koran
2001). Reasons for such dropout were adverse effects, insufficient
response, intercurrent illness, or dispute with staff. Two studies
reported the occurrence of any adverse events, including adverse
effects (e.g. headache, insomnia, sexual problems) for the majority
of participants (Keller 1998b), and adverse effects (especially sleep
disturbances and sexual problems) for all participants in the
medication arm (Harrison 1986), although Harrison 1986 reported
no data for the placebo group.
Excluded studies
The major reason for exclusion of studies was the non-fulfilment
of the diagnosis 'persistent depressive disorder' (see Figure 1).
Some studies involved participants with recurrent depressive
disorder with complete interepisode remission (e.g. Jarrett 2013),
other studies also involved chronic forms of depression, but the
percentage of chronic forms was less than 80% (e.g. Thase 2001)
or provided no separate analyses of diagnostic subgroups of
persistent depression (e.g. Petersen 2010). Other studies did not
apply clear response or remission criteria for participants to be
eligible for entering continuation/maintenance treatment (i.e. all
participants from the acute phase could take part in the following
treatment phases) (e.g. Schramm 2017).
Risk of bias in included studies
Of the 10 included studies, seven were RCTs and three were NRCTs.
These three NRCTs were continuation treatment studies (Kocsis
1995; Kocsis 2003; Koran 2001), and were labelled as NRCTs for
this review as the acute-phase responders were not rerandomized
for the continuation treatment. We used the 'Risk of bias' tool
on a three-point scale (low/high/unclear risk) for the RCTs (Figure
2; Figure 3). We used the ROBINS-I tool (Sterne 2016), using a
five-point scale (low/moderate/serious/critical/unclear risk) for the
NRCTs (Figure 4; Figure 5; Table 2; Table 3; Table 4).
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included seven randomized controlled trials. Blank space in rows containing no information indicate
missing information on the 'Risk of bias' scale for the three non-randomized controlled trials.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included
randomized controlled trial (seven studies). Blank space in rows containing no information indicate missing
information on the 'Risk of bias' scale for the three non-randomized controlled trials.
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Figure 4.   Risk of bias graph non-randomized controlled trials (NRCT): review authors' judgement about each risk of
bias item presented as percentages across all included NRCTs (three studies).
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Figure 5.   Risk of bias summary non-randomized controlled trials (NRCT): review authors' judgements about each
risk of bias item for each included NRCT (three studies).
 
Risk of bias in randomized controlled trials (seven studies)
Random sequence generation (selection bias)
None of the included RCTs described random sequence generation
(unclear risk of bias in all seven RCTs).
Allocation (selection bias)
All seven RCTs had an unclear risk of bias concerning allocation as
there was no information on the allocation process.
Blinding (performance bias and detection bias)
Blinding of participants and personnel (performance bias)
Five RCTs reported that participants and personnel were blinded
(low risk) (Gelenberg 2003; Harrison 1986; Keller 1998b; Kocsis
1996; Miller 2001). Two RCTs were psychotherapy studies
(Hellerstein 2001; Klein 2004). Therefore, participants and
personnel were aware of the treatment condition (high risk).
Blinding of outcome assessment (detection bias)
In two RCTs, the outcome assessors were independent and blind
to the treatment condition (low risk; Gelenberg 2003; Klein 2004).
In two RCTs, there was no information on this domain (unclear
risk; Harrison 1986; Keller 1998b). In three RCTs, the assessors were
study clinicians not blinded to the treatment condition (high risk;
Hellerstein 2001; Kocsis 1996; Miller 2001).
Incomplete outcome data (attrition bias)
In five RCTs, the risk concerning incomplete outcome data was
low (Gelenberg 2003; Harrison 1986; Klein 2004; Kocsis 1996; Miller
2001). In these studies, the number of participants with missing
data was low (below 5%), there were no missing data, or the (main)
outcome was reported for all included participants. Two RCTs had a
high risk of bias as the number of participants with missing data was
very high, and we considered the used imputation methods (last
observation carried forward (LOCF)) as rather inadequate for this
context (see Discussion) (Hellerstein 2001; Keller 1998b).
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Selective reporting (reporting bias)
Five RCTs had an unclear risk concerning reporting bias (Gelenberg
2003; Harrison 1986; Hellerstein 2001; Keller 1998b; Klein 2004).
There were no study protocols for the continuation or maintenance
treatments available. Nevertheless, we did not rate the risk of bias
as high as outcomes in relevant domains were reported and there
was no specific indication for selective reporting. Two RCTs were
at high risk as results were not reported for all applied measures
(Kocsis 1996; Miller 2001).
Other potential sources of bias
To operationalize the domain of other relevant sources of bias,
we assessed three subdomains separately: insufficient treatment
adherence, allegiance bias/conflict of interest, and attention bias.
Ratings from these three subdomains were then summarized to
one overall rating of 'other potential sources of bias' for each RCT
(see Figure 3 and Characteristics of included studies table). If one
of these three subdomains was at high risk of bias, we assessed
the overall rating as high. In the case that two (or three) domains
indicated an unclear risk and one (or no) domain indicated a low
risk, the overall rating was unclear. The overall rating was low risk
if two or three domains indicated a low risk and no or one domain
indicated an unclear risk.
Three studies were at high risk, especially because conflict of
interest was considered very likely (pharmaceutical sponsoring)
(Gelenberg 2003; Hellerstein 2001; Keller 1998b). One study had
an unclear risk as information on the three subdomains was
mostly lacking (Harrison 1986). Three studies had a low risk
as there was – for example – serum level control to ensure
the treatment adherence (Klein 2004; Kocsis 1996; Miller 2001).
Moreover, the investigators ensured that all groups received the
same amount of attention and there were – in case of sponsoring
from a pharmaceutical company – also other, independent authors
involved in the publication.
Risk of bias in non-randomized controlled trials (three studies)
Bias due to confounding (mostly: group allocation)
Two NRCTs were at low risk of bias due to confounding as
participants were randomized before the acute treatment (Kocsis
2003; Koran 2001). In one NRCT, there was no information on how
participants were allocated to the groups in the acute treatment
phase (unclear risk; Kocsis 1995).
Bias in selection of participants into the study
Two NRCTs included all eligible participants and described the
process of inclusion and the study flow clearly (Kocsis 2003; Koran
2001). Kocsis 1995 included participants from three different acute-
phase treatment protocols with different treatment durations and
medication, thus the risk was moderate.
Bias in classification of interventions
All three NRCTs defined the intervention status well, for example,
the planned and actual dose of the pharmacological intervention
and the number of psychotherapy sessions was described,
indicating a low risk (Kocsis 1995; Kocsis 2003; Koran 2001).
Bias due to departures from intended interventions
In all three NRCTs, there was no indication for departures from
intended interventions (e.g. plasma level checks were performed
and the dose range of medication or the number of psychotherapy
sessions were within the planned range (Kocsis 1995; Kocsis 2003;
Koran 2001). Therefore, the risk was low.
Bias due to missing data
In the studies of Koran 2001 and Kocsis 2003, the number of
participants with missing data was low (less than 5% for the main
outcome) and comparable across the intervention groups. The risk
was moderate for Kocsis 1995, as the proportions of participants
with missing data differed substantially across the groups, but
reasons for dropout were reported.
Bias in measurement of outcomes
The assessment methods were reliable, comparable across
treatment groups and performed by trained independent raters in
the studies of Koran 2001 and Kocsis 2003. In the study of Kocsis
1995, the frequency of ratings differed across treatment groups and
participants and raters were aware of the treatment (serious risk).
Bias in selection of the reported result
In the study of Koran 2001, the outcomes correspond to the ones
named in the methods section. The study protocol focused solely
on the acute phase of the study, and not all measures described in
the protocol were reported in the publication of the continuation
treatment study (moderate risk). For the study reported by Kocsis
2003, no study protocol was available, but all measures reported
in the methods section were also reported in the results section
(moderate risk). In the study reported by Kocsis 1995, the risk of bias
was rated as serious as not all predefined outcomes were reported.
Effects of interventions
See: Summary of findings for the main comparison
For all comparisons, we analyzed ITT data when possible. Six
studies reported ITT data for all outcome measures included in this
review. In the other four studies, data for 2% to 10% (Hellerstein
2001; Kocsis 1996; Kocsis 2003; Koran 2001) of the ITT sample were
missing for single outcome measures at the end of the intervention.
Missing data were not replaced, calculations were based on the
data provided in the publications. Data on the dropout rate (overall
dropout and dropout due to adverse events) were consistently
based on the complete ITT sample. The only study with follow-
up data provided data on depression severity at follow-up for the
complete ITT sample and data on quality of life at follow-up for 85%
of the participants of the ITT sample (Hellerstein 2001).
1. Pharmacological continuation and maintenance therapies
versus placebo
Five studies compared pharmacological continuation and
maintenance therapies with placebo. Keller 1998b compared
sertraline (participants = 77) with placebo (participants = 84),
Harrison 1986 compared phenelzine (participants = 5) with
placebo (participants = 7), and Gelenberg 2003 compared
nefazodone (participants = 76) with placebo (participants = 84).
Both Kocsis 1996 and Miller 2001 compared desipramine with
placebo, analyzing different diagnostic subgroups: Kocsis 1996
(desipramine: participants = 28; placebo: participants = 25), Miller
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2001 (desipramine: participants = 14; placebo: participants = 13). As
Kocsis 1996 and Miller 2001 evaluated partially overlapping groups
(see above), we considered only the data of the larger group (Kocsis
1996) here. The sample of Kocsis 1996 was replaced by the sample
of Miller 2001 in the sensitivity analyses.
Primary outcomes
1.1. Relapse/recurrence rates of depression
The four included studies were all RCTs. Three of them
were maintenance treatment studies (Gelenberg 2003; Keller
1998b; Kocsis 1996), while Harrison 1986 was a continuation
treatment study. All studies used different antidepressants from
varying classes. Participants taking antidepressant medication had
significant fewer relapses or recurrences compared to the placebo
group at end of the intervention, with moderate heterogeneity (RR
0.41, 95% CI 0.21 to 0.79; participants = 383; studies = 4; I2 = 54%;
Analysis 1.1; Figure 6). This translated to an NNTB of six.
 
Figure 6.   Forest plot of comparison: 1 Medication versus placebo, outcome: 1.1 Relapse/recurrence.
 
1.2. Dropout due to any reason
Four RCTs provided overall dropout rates at the end of
the intervention. Three were maintenance treatment studies
(Gelenberg 2003; Keller 1998b; Kocsis 1996), while Harrison 1986
was a continuation treatment study. We found no significant
differences between medication and placebo, with substantial
heterogeneity (RR 0.90, 95% CI 0.39 to 2.11; participants = 386; I2
= 64%; Analysis 1.2). Two studies reported fewer dropouts in the
medication arm (Gelenberg 2003; Kocsis 1996), while the other two
studies reported fewer dropouts in the placebo group (Harrison
1986; Keller 1998b).
Secondary outcomes
1.3. Symptom severity of depression
Three RCTs provided means and standard deviations (SDs). Two
were maintenance treatment studies (Gelenberg 2003; Keller
1998b), while Harrison 1986 was a continuation treatment study.
Participants in the medication groups showed a significantly lower
symptom severity on the HAM-D at the end of the intervention
compared to the placebo groups, with moderate to substantial
heterogeneity (MD –4.79, 95% CI –8.49 to –1.09; participants = 333;
I2 = 60%; Analysis 1.3).
1.4. Health-related quality of life
One RCT provided quality of life measures at the end of the
intervention and reported three subscales of the SF-36 (Keller
1998b). In this maintenance treatment study, participants in the
medication group reported both higher social functioning (MD
10.80, 95% CI 3.04 to 18.56; participants = 161; Analysis 1.4) and
fewer limitations owing to emotional problems (MD 20.70, 95%
CI 7.43 to 33.97; participants = 161; Analysis 1.5). There was no
significant difference between groups for the subscale of role
limitations owing to physical health problems (Analysis 1.6).
1.5. Dropout due to any type of adverse events
Three RCTs provided data on dropouts due to adverse events at
the end of the intervention. Two were maintenance treatment
studies (Gelenberg 2003; Keller 1998b), while Harrison 1986 was a
continuation treatment study. There was no significant difference
between medication and placebo groups (OR 3.53, 95% CI 0.67 to
18.70; participants = 333; I2 = 46%; Analysis 1.7).
1.6. Any type of adverse event
One RCT provided data on experiencing any adverse event (physical
problems such as headache or insomnia) at the end of the
intervention (Keller 1998b). In this maintenance treatment study,
there was no significant difference between medication and
placebo (OR 1.47, 95% CI 0.70 to 3.09; participants = 161; Analysis
1.8). The continuation treatment study of Harrison 1986 (RCT) also
provided data on adverse events, but solely for the medication
group. In the medication group all participants had adverse events.
1.7. Serious adverse events
We found no studies reporting participants experiencing serious
adverse events.
2. Pharmacological continuation and maintenance therapies
versus treatment as usual
None of the included studies compared pharmacological
continuation and maintenance therapies versus TAU.
3. Psychological continuation and maintenance therapies
versus attention placebo/non-specific control
One maintenance treatment study (RCT) provided data on the
comparison psychotherapy versus assessment only (Klein 2004).
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Primary outcomes
3.1. Relapse/recurrence rates of depression
Rates of relapse/recurrence were significantly lower in the
psychotherapy group (RR 0.37, 95% CI 0.14 to 0.93; participants =
82; Analysis 2.1). This translated to an NNTB of five.
3.2. Dropout due to any reason
There were no significant differences between the overall dropout
rates (RR 0.87, 95% CI 0.41 to 1.81; participants = 82; Analysis 2.2).
Secondary outcomes
3.3. Symptom severity of depression
Depression severity was significantly lower in the psychotherapy
group at the end of the intervention (MD –4.00, 95% CI –7.05 to –
0.95; participants = 82; Analysis 2.3).
3.4. Health-related quality of life
The study did not report health-related quality of life.
3.5. Dropout due to any type of adverse events
The study did not report dropout due to any type of adverse events.
3.6. Any type of adverse event
The study did not report participants experiencing any type of
adverse event.
3.7. Serious adverse events
The study did not report participants experiencing serious adverse
events.
4. Psychological continuation and maintenance therapies
versus treatment as usual
None of the included studies compared psychological continuation
and maintenance therapies versus TAU.
5. Psychological continuation and maintenance therapies
versus pharmacological continuation and maintenance
therapies
One continuation treatment study (NRCT) provided data on the
comparison psychotherapy versus medication (Kocsis 2003).
Primary outcomes
5.1. Relapse/recurrence rates of depression
There were no significant differences in relapse/recurrence rates
between groups (RR 1.22, 95% CI 0.43 to 3.49; participants = 176;
Analysis 3.1).
5.2. Dropout due to any reason
There were no significant differences in dropout rates
between groups, although there was a tendency favouring
psychotherapeutic treatment (RR 0.56, 95% CI 0.30 to 1.03;
participants = 179; Analysis 3.2).
Secondary outcomes
5.3. Symptom severity of depression
The study did not report depression severity scales.
5.4. Health-related quality of life
The study did not report health-related quality of life.
5.5. Dropout due to any type of adverse events
The study did not report dropout due to any type of adverse events.
5.6. Any type of adverse event
The study did not report participants experiencing any type of
adverse event.
5.7. Serious adverse events
The study did not report participants experiencing serious adverse
events.
6. Combined psychological and pharmacological continuation
and maintenance therapies versus pharmacological
continuation and maintenance therapies alone
Two continuation treatment studies compared combined
psychological and pharmacological continuation and maintenance
therapies versus pharmacological continuation and maintenance
therapies alone: Kocsis 2003 (NRCT) compared nefazodone
(participants = 91) with nefazodone plus CBASP (participants = 150),
while Hellerstein 2001 (RCT) compared fluoxetine only (participants
= 19) with fluoxetine plus group psychotherapy (participants = 20).
Primary outcomes
6.1. Relapse/recurrence rates of depression
Kocsis 2003 (NRCT) provided data on relapse/recurrence rates,
showing no significant difference between participants taking
medication only (nefazodone) or medication combined with
psychotherapy (CBASP) (RR 1.23, 95% CI 0.44 to 3.44; participants
= 238; Analysis 4.1).
6.2. Dropout due to any reason
Both studies provided overall dropout rates at the end of
the intervention and found no significant differences between
medication only and the combined treatment, with no
heterogeneity (RR 1.43, 95% CI 0.90 to 2.29; participants = 280; I2 =
0%; Analysis 4.2).
Secondary outcomes
6.3. Symptom severity of depression
One RCT provided continuous data on depression severity scale
(Hellerstein 2001). Participants in the combined treatment group
showed significantly lower symptom severity on the HAM-D at the
end of the intervention compared to the medication only group
(MD 2.80, 95% CI 0.38 to 5.22; participants = 39; Analysis 4.3). This
study also provided follow-up data 12 weeks aRer the end of the
intervention. There was no significant differences between both
groups (MD 0.90, 95% CI –3.26 to 5.06; participants = 39; Analysis
4.4).
6.4. Health-related quality of life
Hellerstein 2001 (RCT) provided health-related quality of life
measures at the end of the intervention and at follow-up 12
weeks aRer the end of the intervention. There were no significant
differences between groups at either time point, using the SWLS
(end: MD –0.50, 95% CI –1.63 to 0.63; participants = 35; Analysis 4.5;
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follow-up: MD 0.60, 95% CI –0.56 to 1.76; participants = 33; Analysis
4.6).
6.5. Dropout due to any type of adverse events
Neither study reported dropout due to any type of adverse events.
6.6. Any type of adverse event
Neither study reported participants experiencing any type of
adverse event.
6.7. Serious adverse events
Neither study reported participants experiencing serious adverse
events.
7. Combined psychological and pharmacological continuation
and maintenance therapies versus psychotherapeutic
continuation and maintenance therapies alone
One continuation treatment study (NRCT) provided data on the
comparison psychotherapy (CBASP, participants = 88) versus
combined treatment (nefazodone plus CBASP, participants = 150)
(Kocsis 2003).
Primary outcomes
7.1. Relapse/recurrence rates of depression
There was no difference in rates of relapse/recurrence between
groups (RR 1.51, 95% CI 0.57 to 4.01; participants = 234; Analysis
5.1).
7.2. Dropout due to any reason
There was no difference in overall dropout rates at the end of
the intervention between groups (RR 0.82, 95% CI 0.45 to 1.51;
participants = 238; Analysis 5.2).
Secondary outcomes
7.3. Symptom severity of depression
The study did not report depression severity scales.
7.4. Health-related quality of life
The study did not report health-related quality of life.
7.5. Dropout due to any type of adverse events
The study did not report dropout due to any type of adverse event.
7.6. Any type of adverse event
The study did not report participants experiencing any type of
adverse event.
7.7. Serious adverse events
The study did not report participants experiencing serious adverse
events.
8. Comparison of different antidepressant medications (post
hoc analyses)
Two continuation treatment studies (NRCTs) compared two
different antidepressant medications (Kocsis 1995; Koran 2001).
Although we did not predefine this comparison as a main
comparison of interest in the study protocol, we opted to report
these additional data.
8.1. Imipramine versus desipramine
One study provided data on the comparison of two different TCAs
(imipramine and desipramine) (Kocsis 1995).
Primary outcomes
8.1.1. Relapse/recurrence rates of depression
The study did not report relapse/recurrence rates of depression.
8.1.2. Dropout due to any reason
Significantly more participants dropped out in the imipramine
group (RR 4.35, 95% CI 1.19 to 15.87; participants = 73; Analysis 6.1).
This translated to an NNTB of five, that is, five participants must
have been treated with desipramine to maintain one additional
participant in treatment.
Secondary outcomes
8.1.3. Symptom severity of depression
The study did not report depression severity scales.
8.1.4. Health-related quality of life
The study did not report health-related quality of life.
8.1.5. Dropout due to any type of adverse events
There were no significant differences in dropout rates due to
adverse events between groups (OR 1.49, 95% CI 0.23 to 9.60;
participants = 73; Analysis 6.2).
8.1.6. Any type of adverse event
The study did not report participants experiencing any type of
adverse event.
8.1.7. Serious adverse events
The study did not report participants experiencing serious adverse
events.
8.2. Imipramine versus sertraline
One study compared a TCA (imipramine) with an SSRI (sertraline)
(Koran 2001).
Primary outcomes
8.2.1. Relapse/recurrence rates of depression
There were no significant differences in relapse/recurrence rates
between groups (RR 1.27, 95% CI 0.84 to 1.91; participants = 376;
Analysis 7.1).
8.2.2. Dropout due to any reason
There were no significant differences in overall dropout rates
between groups (RR 0.81, 95% CI 0.48 to 1.38; participants = 386;
Analysis 7.2).
Secondary outcomes
8.2.3. Symptom severity of depression
There was no significant difference in depression severity
(measured with the HAM-D) at the end of the intervention between
groups (MD 0.40, 95% CI –0.97 to 1.77; participants = 377; Analysis
7.3).
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8.2.4. Health-related quality of life
The degree of enjoyment and satisfaction in different areas of
daily functioning (Q-LES-Q) at the end of the intervention was
significantly higher in the sertraline group (MD –4.30, 95% CI –7.31
to –1.29; participants = 347; Analysis 7.4).
8.2.5. Dropout due to any type of adverse events
There were no significant differences in dropout rates due to
adverse events between groups (OR 1.99, 95% CI 0.60 to 6.65;
participants = 386) (Analysis 7.5).
8.2.6. Any type of adverse event
The study did not report participants experiencing any type of
adverse event.
8.2.7. Serious adverse events
The study did not report participants experiencing serious adverse
events.
Subgroup analyses
We were unable to perform any of the a priori defined subgroup or
meta-regression analyses due to limited number of studies.
Sensitivity analyses
We could perform sensitivity analyses only for one comparison
(pharmacological continuation and maintenance therapies versus
placebo) as all other comparisons did not provide enough data.
Excluding studies with a high or unclear risk of bias
For each risk of bias domain, we planned to exclude the studies with
high or unclear risk to compare these results with the results of the
analysis including all studies.
For the domains 'random sequence generation', 'allocation
concealment', and 'selective reporting', none of the studies had a low
risk of bias, thus these sensitivity analyses could not be performed.
For the domain 'blinding of participants and personnel', all of these
studies had a low risk of bias.
For the domain 'blinding of outcome assessment', only Gelenberg
2003 had a low risk of bias. When including only Gelenberg 2003,
the difference between medication and placebo for relapse or
recurrence rate of depression did not reach significance (RR 0.76,
95% CI 0.47 to 1.23; P = 0.27), whereas for dropout due to any
reason, there was a significant difference favouring medication (RR
0.48, 95% CI 0.24 to 0.94; P = 0.03). For depression severity, the
difference between medication and placebo was not significant
when including Gelenberg 2003 only (MD –2.10, 95% CI –5.08 to
0.88; P = 0.17). For dropout due to any type of adverse event, there
was no significant difference between medication and placebo,
which was consistent with the original results.
For the domain 'incomplete outcome data', we excluded Keller
1998b as it had a high risk of bias. There was no change for
relapse or recurrence rate of depression or dropout due to any
reason (except a lower rate of heterogeneity for dropout due to
any reason). For severity of depression, the heterogeneity increased
when excluding Keller 1998b. Medication was still superior to
placebo but the differences between the two groups was not
significant (MD –5.63, 95% CI –14.17 to 2.90; P = 0.20). For dropout
due to any type of adverse event, the results did not change
substantially when excluding Keller 1998b.
For the domain 'other potential sources of bias', the studies of Kocsis
1996 and Miller 2001 (comparing desipramine with placebo) with
the partially overlapping subgroup had a low risk of bias. Including
only Kocsis 1996, the difference between medication and placebo
for relapse or recurrence rate of depression remained significant.
For dropout due to any reason, the difference between medication
and placebo was not significant, corresponding to the original
results. For severity of depression and dropout due to any type of
adverse event there were no data available for Kocsis 1996.
In summary, the sensitivity analyses could only focus on three of
the seven risk of bias domains and on the two primary outcomes
(relapse or recurrence rate of depression, dropout due to any
reason) and on two secondary outcomes (severity of depression,
dropout due to any type of adverse event).
Excluding trials without a randomization on a personal level or
without (re)randomization before the continuation phase
We could not perform these analyses as all studies
providing data on the comparison pharmacological continuation
and maintenance therapies versus placebo were RCTs with
randomization on a personal level.
Post hoc sensitivity analyses
As there were two partially overlapping groups included in our
review regarding the comparison pharmacological continuation
and maintenance therapies versus placebo (Kocsis 1996; Miller
2001), we decided to perform an a posteriori defined sensitivity
analysis (including Miller 2001 instead of Kocsis 1996). Miller
2001 investigated the dysthymic subsample of Kocsis 1996 but
also included additional people with dysthymia. Miller 2001 only
provided data on relapse or recurrence rate of depression. The
RR was slightly lower with a broader CI and a slightly higher
heterogeneity when including Miller 2001 instead of Kocsis 1996
(RR 0.38, 95% CI 0.16 to 0.89; I2 = 58%; Analysis 1.9). We considered
these differences as clinically not meaningful.
D I S C U S S I O N
Summary of main results
This review was based on data from 10 studies, from which
five studies investigated continuation treatments and five studies
investigated maintenance treatments. All maintenance treatment
studies and two continuation treatment studies applied an
RCT design. The remaining three continuation treatment studies
used an NRCT design. Five studies included comparisons of
antidepressant medication versus tablet placebo. Only three
studies involved psychological treatment. Two of these three
studies investigated the effect of the Cognitive Behavioral Analysis
System of Psychotherapy (CBASP) compared to antidepressant
medication or combined treatment, or against assessment only,
while the other study compared antidepressant medication to
medication plus group therapy. We also analyzed data for a
posteriori defined comparison, the direct comparison of two
antidepressants. All 10 studies reported data at the end of the
intervention, while only one study also reported follow-up data 12
weeks aRer the end of the intervention.
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Pharmacological continuation and maintenance therapies
versus placebo
Five studies compared continuation or maintenance
antidepressant medication with tablet placebo. The class of
antidepressant medication varied between the included studies,
SSRIs, MOIs, SNDRIs, and TCAs were used. For the analyses, we
excluded one study (Miller 2001), due to an overlapping group of
participants with the study of Kocsis 1996 and included four studies
involving 383 participants in our analyses. There was moderate
quality of evidence that participants taking antidepressant
medication had significantly fewer relapses or recurrences and a
lower depressive symptom severity score compared to participants
taking placebo at the end of the intervention. The results did
not change significantly when replacing Kocsis 1996 by Miller
2001. However, the sensitivity analysis showed that the difference
between medication and placebo for relapse or recurrence rate
of depression and depression severity was not significant when
the only study (Gelenberg 2003) with low risk of bias for assessor
outcome blinding was included.
Continuation/maintenance antidepressant medication reduced
risk of relapse or recurrence rate of depression with an NNTB of
six. Heterogeneity between studies was moderate. For the outcome
relapse or recurrence rate of depression, three studies showed
similar between-group effect sizes, although these studies varied
largely regarding treatment duration and sample size (Harrison
1986; Keller 1998b; Kocsis 1996). In comparison, in Gelenberg
2003, the effect favouring medication was smaller with a rather
narrow CI, and as explained above, sensitivity analyses revealed
that this effect was not significant when only including Gelenberg
2003. Miller 2001 showed a very strong effect favouring medication
with a very large CI (due to small sample size). In Miller 2001,
solely participants with dysthymia were treated over a period
of 104 weeks, therefore the design and setting of this study is
different from the other four studies. Besides, all studies used
different antidepressants from varying classes, which could have
contributed to the moderate degree of heterogeneity.
We found no significant differences between medication and
placebo concerning the overall dropout rate. However, the quality
of evidence for this result was rated as low. Heterogeneity was
substantial (I2 = 64%). In Harrison 1986, no participant in the
placebo group dropped out, but they reported that all participants
in the placebo group relapsed (therefore a dropout due to other
reasons than relapse/recurrence was not possible by definition).
In addition, two studies investigated rather small sample sizes,
resulting in large CIs (Harrison 1986; Kocsis 1996).
Participants taking antidepressant medication had a significantly
lower depressive symptom severity score compared to participants
taking placebo at the end of the intervention (based on three RCTs).
Two of these studies, both maintenance treatment studies, showed
very similar results, both in means and SDs pre- and post-treatment
and generally, in design of the study (maintenance phase, lasting
52 weeks (Gelenberg 2003) or 76 weeks (Keller 1998b)). Treatment
duration in the continuation treatment study of Harrison 1986 was
26 weeks, and participants in the medication arm reported lower
and participants in the placebo group higher symptom severity
scores compared to the corresponding groups in the other two
studies. These factors might have contributed to considerable
heterogeneity between the three studies.
Regarding relapse or recurrence rate of depression and severity of
depression, the results are unconvincing whether or not continued
or maintained (or both) pharmacotherapy was superior to tablet
placebo in persistent depressed participants.
Three RCTs provided data on dropout due to any type of adverse
event at the end of the intervention and low quality of evidence
indicated no significant difference between medication and
placebo (Gelenberg 2003; Harrison 1986; Keller 1998b). These three
studies varied in sample size, dropout rates due to adverse events
in general and between treatment arms, potentially contributing
to the moderate degree of heterogeneity. In the continuation
treatment study of Harrison 1986, no participant in the placebo
group dropped out due to adverse events, but all of these
participants relapsed (before), and this study had a small sample
size and rather short treatment duration compared to the other two
studies. The maintenance treatment study of Keller 1998b showed
considerable differences in dropout rates between the groups,
favouring placebo, and treatment lasted 76 weeks. In comparison
to the other two studies, Gelenberg 2003 showed the smallest
difference in dropout rates due to an adverse event between the
medication and placebo group during the maintenance treatment
phase. It was unclear if participants actually took the medication
throughout the entire maintenance phase as no laboratory tests
were reported (see Characteristics of included studies table). This
could possibly lead to less reporting of adverse events.
One study provided quality of life measures, in which participants
in the medication group benefited compared to placebo (Keller
1998b).
Psychological continuation and maintenance therapies versus
attention placebo/non-specific control
One maintenance treatment study with 52 weeks' duration,
involving 82 participants, compared psychological continuation
and maintenance therapies versus attention placebo/non-specific
control (Klein 2004). The study showed fewer relapse or recurrence
rate of depression and a lower depression severity score in the
CBASP group compared to the assessment-only group at the end
of the intervention. Maintained CBASP treatment reduced the risk
of relapse or recurrence with an NNTB of five. Overall dropout
rates were similar in both treatment arms. It might be assumed
that maintained active psychotherapy has a positive effect on
depression outcomes compared to assessment only.
Psychological continuation and maintenance therapies versus
pharmacological continuation and maintenance therapies
Only one study, involving 179 participants, provided data on the
active comparison of psychotherapy with medication during the
continuation treatment phase (Kocsis 2003). Although participants
receiving CBASP and participants taking nefazodone did not differ
regarding relapse or recurrence of depression and overall dropout
rate at the end of the intervention, there was a tendency favouring
psychotherapeutic treatment observable regarding dropout.
Combined psychological and pharmacological continuation
and maintenance therapies versus pharmacological
continuation and maintenance therapies alone
Three studies compared combined psychological and
pharmacological continuation and maintenance therapies versus
pharmacological continuation and maintenance therapies alone.
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One continuation treatment study, involving 238 participants,
provided relapse or recurrence rates of depression and showed
no statistically significant differences between the group taking
nefazodone and the group receiving CBASP plus nefazodone
(Kocsis 2003). Two studies, involving 280 participants, provided
overall dropout rates, showing no statistically significant
differences between medication alone and the combined
treatment (Hellerstein 2001; Kocsis 2003). One study, involving 39
participants, reported a significant lower depression severity score
for the combined group compared to medication alone at the end
of the intervention (Hellerstein 2001). However, this effect did not
remain at 12 weeks' follow-up. This same study provided quality of
life measures, and found no differences between groups at the end
of the intervention and follow-up.
Combined psychological and pharmacological continuation
and maintenance therapies versus psychotherapeutic
continuation and maintenance therapies alone
One continuation treatment study, involving 238 participants,
compared combined psychological and pharmacological
continuation and maintenance therapies versus psychotherapeutic
continuation and maintenance therapies alone. It found no
significant differences for relapse or recurrence of depression and
overall dropout rates between the CBASP group and the CBASP plus
nefazodone group (Kocsis 2003).
Comparison of different antidepressant medications (post hoc
analyses)
Two studies reported data on the direct comparison of two
antidepressants. One continuation treatment study, involving 73
participants, compared two TCAs, where overall dropout rates were
higher in the imipramine group compared to the desipramine group
(Kocsis 1995). Compared to imipramine, desipramine reduced the
dropout risk with a NNTB of five. Dropout rates due to any type
of adverse events did not differ significantly between the two
groups. The imipramine sample was relatively small (participants
= 23) and only half the size of the desipramine sample. The
three dropouts in the desipramine group dropped out due to
dissatisfaction with treatment response or due to adverse effects.
In the imipramine group, one participant discontinued because of
adverse effects, one participant had a dispute with the staff, and
four participants did not comply with the follow-up assessment.
Data on relapse or recurrence rates of depression were not provided
in this comparison.
The second study, a continuation treatment study involving 386
participants, compared a TCA with an SSRI, showing no significant
differences between groups regarding relapse or recurrence of
depression, overall dropout rate, dropout rate due to any type of
adverse events, and severity of depression severity at the end of
the intervention (Koran 2001). This study provided quality of life
measures, in which participants of the SSRI group reported a
significantly higher quality of life at the end of the intervention.
Overall completeness and applicability of evidence
Only 10 studies were identified for inclusion in this review. Most
of the studies retrieved in the search could not be included in
the review as: they treated solely participants with recurrent
depression (with clear interepisode remission and an episode
duration shorter than two years); they did not clearly assess
the percentage of diagnostic subgroups of persistent depressive
disorder; or they reported no subgroup analyses. Thus, it can be
assumed that there are more studies available involving people
with persistent depression, but as no specific percentages were
available from the publications or following contact with the
authors, these data could not be considered for this review.
Moreover, some long-term studies had to be excluded because they
did not define clear response or remission criteria for entering the
next treatment phase which we required for inclusion in the review
as response or remission are considered as accurate criteria of
continuation or maintenance treatments (Frank 1991). Overall, this
resulted in a rather small body of evidence available for addressing
the objectives of this review.
Regarding the 10 included studies, for most comparisons
only one or two studies provided data for the analyses,
limiting the informative value of the presented results. For
the comparison of antidepressant medication and placebo, five
studies provided consistent data although they used different
classes of medication. Only three of the included studies
involved psychological treatments, two of them applied to
individual participants (CBASP), the other applied as a group
therapy, both conducted in an outpatient setting in the US.
More studies are required to evaluate the different forms of
psychotherapy (e.g. IPT, CBT, CBASP, MBCT, psychodynamic
therapy) in varying treatment settings (individual, group), cultures,
and healthcare systems. Moreover, just two studies investigated
the combination of psychotherapy and antidepressant medication
although guidelines already recommend combined treatment for
persistent depressive disorders (DGPPN 2015). Also, we expected
to include comparisons with TAU, investigating if long-lasting
continuation and maintenance treatments are implemented in
healthcare systems and evaluating these treatments under natural
conditions. Unfortunately, we identified no studies using this
comparator.
From the 10 included studies, five were continuation studies and
five were maintenance studies. Maintenance treatment studies
varied largely regarding the duration of treatment (12 to 24
months), while the preceding continuation treatment studies
were more similar in duration (16 to 20 weeks). Per definition,
participants remitted or at least partially responded during acute
treatment should start continuation treatment within one year
aRer terminating acute treatment. Then, maintenance treatments
should be given during recovery, which is defined as remission
lasting longer than six months (Frank 1991; NICE 2010). Three
studies providing a continuation treatment phase defined a
duration of 16 to 20 weeks' treatment before participants entered
a subsequent maintenance phase. This does not correspond to the
recommended criterion of six months' recovery before entering
maintenance treatment. Still, we decided to include these studies
in the review and followed the definition of the authors as they
described reasonable criteria for participants being eligible to
enter the maintenance phase. We kept the term 'maintenance
treatment' for these treatments as they were longer than the
examined continuation treatments, consistently. Due to the small
amount of included studies, we did not differentiate between
effects of continuation versus maintenance treatments during the
analyses, which would be valuable considering the distinct criteria
of remission/recovery for both treatment phases. Particularly in
persistent depressive disorder with participants showing severe
levels and duration of symptoms, clear criteria for receiving both
treatments following acute therapy are required. Therefore, a
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)









Cochrane Database of Systematic Reviews
consistent application of the terms continuation and maintenance
treatment and corresponding implementation into research and
health care is needed before definite conclusions about the
effectiveness of such treatments can be drawn.
For this review, the primary efficacy outcome was relapse or
recurrence. Most of the studies applied rather strict criteria
for participants to fulfil this outcome criterion at the end of
the intervention (e.g. exceeding cut-offs during two or three
consecutive sessions followed by a personal interview with a study
investigator clarifying a potential diagnosis). Such procedures
contribute to keeping participants longer in the study programme
and possibly underestimate absolute relapse and recurrence rates.
Different definitions of this outcome between the included studies
also prevent a comparison of absolute relapse/recurrence rates
between the examined treatments. Additionally, it must be kept
in mind that two different target figures were mixed here: relapse
defined the return of symptoms before full remission was reached,
while recurrence indicated a new episode aRer a full remission had
been reached.
The primary acceptance outcome was dropout due to any reason
(other than relapse/recurrence), of which nine of the 10 studies
reported data. Specific reasons for dropout and specific adverse
events were rarely described. Instead, general statements about
adverse events were reported (e.g. that adverse effects evolved in
at least 10% of participants). But, next to adverse effects, other
negative events such as interpersonal problems (e.g. conflicts
with others) might occur during or aRer treatment. Such adverse
events were reported very rarely in the included studies of this
review, but should be addressed clearly in future research (Meister
2016). Especially in long-term treatments such as continuation and
maintenance treatments, dropout is considered likely and should
be assessed in more detail (e.g. if participants dropped out due to
aspects of the intervention itself or due to other reasons).
Another secondary outcome of interest of this review were
quality of life measures. Only three of the 10 studies addressed
this outcome although psychotherapeutic and pharmacological
treatments are considered to improve quality of life in depressive
disorders (Kamenov 2017). As persistent depressive disorders
are characterized by a chronic course, an exclusive focus on
improvement of depressive symptomatology over a long time
might be too narrow to describe health status of participants
completely. Including quality of life measures more frequently into
studies is recommended.
Moreover, we intended to analyse data at the time point 'one
year aRer the end of the intervention'. Surprisingly, just one
of the 10 studies provided follow-up data, and even this study
addressed a short follow-up duration (12 weeks). Particularly in
persistent depressive disorder, we consider the evaluation of long-
term effects beyond termination of treatment as highly relevant
and valuable information to provide recommendations on when
therapy should be extended, changed, or terminated.
PDD is a rather severe form of depression with people probably
experiencing comorbid disorders including personality disorders,
suicidality or psychotic symptoms, and usually undergoing several
other treatments before entering a study, which in turn was
an exclusion criterion in some of the included studies for this
review. This raises the question about what type of participants
joined the studies we included in this review – severely impaired
or less impaired people? Although these previously mentioned
exclusion criteria were defined (e.g. other mental disorders as main
diagnoses), a high percentage of included participants experienced
comorbid conditions (e.g. in Keller 1998b and Kocsis 1996 half
of the sample had an axis-II-diagnosis). Additionally, anxiety
disorders and substance abuse was highly prevalent in samples
reporting comorbid conditions. Further, as lifetime duration of
depression ranged from 15 to 24 years, we can assume that –
despite the exclusion criteria – severely impaired participants were
included in our analyses with illness duration and comorbidity rates
comparable to those known from previous research (Gilmer 2005;
Kocsis 2008). However, not all studies reported on comorbidity
and chronicity, so this information was not available for the whole
sample.
Six studies had failing previous trials of antidepressant medication
as an exclusion criterion (i.e. studies excluded so-called treatment-
resistant participants). But, as response is a requirement for
continuation and maintenance treatment, results of those studies
are not applicable to treatment-resistance anyway.
Experience with prior treatment is common in this severely
impaired group and was not an exclusion criterion in the analyzed
studies – especially the experience with psychotherapy was high
(63% to 85%) in the five studies providing data on this issue.
Another aspect regarding the applicability of evidence is date
of publication. Studies included in this review were published
between 1986 and 2004. The current practice including available
medication and psychotherapy for treating people with persistent
forms of depression might have been different at that time. For
example, nefazodone, which was used in two of the included
studies (Gelenberg 2003; Kocsis 2003), was withdrawn from the
market in 2003 (Kocsis 2003) and 2004 (Gelenberg 2003) in some
countries due to the rare incidence of hepatoxicity (Cosgrove-
Mather 2004).
Quality of the evidence
For most of the planned comparisons only one or two studies
provided data. Thus, we reported a 'Summary of findings' table
only for the comparison of pharmacological continuation and
maintenance therapies versus placebo, referring to the quality of
evidence of the primary outcomes relapse/recurrence and overall
dropout.
Limitations in study design or execution (risk of bias)
We included seven RCTs and three NRCTs involving 840 participants
with persistent depressive disorder. Two of the three NRCTs were
evaluated as having almost no risk of bias in the seven domains,
while the other study was classified between moderate and serious
risk for more than half of the domains. The seven included RCTs
varied regarding risk of bias domains, and were rated mostly as low
or unclear risk of bias, with one exception. One study was at high
risk of bias in four domains and unclear risk of bias in three domains
(Hellerstein 2001). In general, none of the studies addressed
allocation concealment and random sequence generation and,
therefore, were at unclear risk, and selective reporting at unclear
risk in five of these seven studies. One study with high risk of bias
in the domain selective reporting analyzed data on dropout during
the 104-week maintenance phase, but only the rates during the first
month of treatment, probably underestimating the actual dropout
rate over time (Kocsis 1996).
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To separate the two primary outcomes (relapse/recurrence and
overall dropout), we did not include the participants with relapse/
recurrence in the overall dropout rates. This must be kept in mind
when interpreting the absolute dropout rates. Additionally, as in
one study, all participants in the placebo group relapsed and there
was no information on the time of relapse, the dropout rate in
this group was zero, possibly overestimating the acceptance of
this treatment. If the participants relapsed early, there was 'no
chance' for accepting or not accepting the treatment. Two studies
reported incomplete outcome data at high risk (Hellerstein 2001;
Keller 1998b), as they applied the LOCF method for imputing
missing values. In Keller 1998b, 70% of the participants in the
placebo group dropped out during the 76-week maintenance
treatment, thus the missing data were replaced by the last
available measure of the participant. Although this method is
commonly used for analyzing longitudinal data, we consider
this procedure inappropriate within the context of continuation/
maintenance treatments as it potentially underestimates relapse
and recurrence rates. As LOCF assumes that the missing data aRer
the participant's dropout stay the same as the last value observed
for that participant (Shih 2002), we assumed that LOCF provided
rather optimistic estimates instead of conservative estimates. This
assumption of stability is rather unlikely for persistent depressive
disorder over long periods of time considering the high likelihood
of recurrences reported in previous research.
Analyses regarding dropout rates for the comparison of
antidepressant medication versus placebo resulted in serious
heterogeneity between studies. Due to the small number of studies,
we were unable to analyse these differences statistically. These
circumstances in combination with the mentioned limitations of
the studies contributed to downgrading the body of evidence
for this comparison regarding the outcome dropout (other than
relapse/recurrence) to low (see Summary of findings for the main
comparison).
Inconsistency of results
Data were inconsistent in regard to overall dropout rates. Dropout
rates varied between studies from 4% (Kocsis 1996) and 100%
(Harrison 1986). This unexplained heterogeneity contributed to
downgrading the quality of evidence to low regarding overall
dropout rates in the comparison of antidepressant medication
versus placebo.
Indirectness of evidence
All included studies directly addressed the objective of this
review, namely the comparative effectiveness of continuation and
maintenance treatments for persistent depressive disorder.
Imprecision of results
Two of four studies addressing overall dropout rates in the
comparison of antidepressant medication versus placebo showed
wide CIs (Harrison 1986; Kocsis 1996). This contributed to
downgrading the quality of evidence to low.
Publication bias
Due to the small number of included studies, we applied funnel
plot only for the comparison antidepressant medication versus
tablet placebo. Apparently, the funnel plot on relapse/recurrence
was asymmetrical, with an overhang of small studies showing a
large difference in favour of medication), while the funnel plot on
dropout was symmetrical. The application of statistical tests (e.g.
Egger's test) for funnel plot asymmetry was not conducted, as it is
not advisable due to the small number of studies. The Cochrane
Handbook for Systematic Reviews of Interventions recommends
these tests when there are at least 10 studies, otherwise the power
is too low (Higgins 2011).
Potential biases in the review process
We used a broad search strategy for identifying all relevant studies
regarding continuation and maintenance treatments in PDD. The
main search was conducted in the specialized register of RCTs of the
Cochrane Common Mental Disorders Group (CCMD-CTR) searching
for study and reference records. Moreover, we searched other
databases, grey literature, clinical trials registers, and contacted
relevant authors in this field. We had to exclude a considerable
number of studies as most either did not include specifically
participants with PDD or did not report the percentage of treated
PDD participants. Although we were in email contact with the first
authors of the included papers regarding this missing information,
they either did not reply to our queries or simply had specific data
no longer available due to conducting these studies several years
ago. Therefore, we assumed that more studies than those included
in this review were conducted with participants with PDD.
At least two review authors independently screened records, and
extracted and analyzed data to prevent any severe bias in the used
methods.
There was marked clinical heterogeneity between the included
studies, especially regarding sample size, subtype of persistent
depression, type of treatment (e.g. type of antidepressant
medication), treatment duration, and definition of relevant
outcomes. Therefore, we are not reporting on a homogeneous
group of participants, manifesting in both studies investigating a
specific subgroup (e.g. solely people with dysthymia) and studies
investigating all four diagnostic subgroups of PDD, making it
difficult to generalize the results to PDD in general. This also
applied to the type of treatment: studies included continuation and
maintenance treatment with lengths between 16 weeks and two
years, which allows no conclusion on continuation or maintenance
treatment in general.
We required the included studies to report on ICD or DSM
diagnosis of PDD, neglecting total duration of illness or other
potential indicators of impairment. But, as we required clear
response or remission criteria for considering continuation or
maintenance treatment studies for this review, symptom level of
included participants was considered rather homogeneous. The
pharmaceutical industry funded some of the included studies
with grants. Conducting long-term continuation and maintenance
studies requires considerable financial support, potentially leading
to bias of the found results if covered by third parties. However,
we considered risk of publication bias as low but the application
of a statistical test was not advisable due to the small number of
studies. Additionally, the required length of treatment – especially
of maintenance studies – is possibly one reason for the lack of
studies in this field.
Another aspect of potential bias was the allowance or prescribing
of concomitant treatments in addition to the treatment provided
by the study. Two of the included studies investigating
antidepressant medication reported that participants received
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ongoing psychotherapy. One study reported that 60% of the
participants received ongoing psychotherapy while treated with
sertraline or imipramine, yet there were no group differences
(Koran 2001). In two studies, about 40% of the participants of
both treatment groups (desipramine, placebo) were on stable long-
term psychotherapy regimens (Kocsis 1996; Miller 2001). Although
parallel treatment is not necessarily considered to bias the results,
especially when proportions are similar between treatment groups,
the observed individual change is not solely based on study
treatment but also on parallel treatment in the respective two
studies. Additionally, interaction effects may occur: 1. the effect
of antidepressant medication could be underestimated because
the received psychotherapy makes an additional treatment
(antidepressant medication) less meaningful or 2. receiving parallel
psychotherapy intensifies the effect of medication or keeps the
participant motivated to stay on medication. However, the other
studies did not mention any information about parallel treatments
or explicitly stated that no concomitant treatment was allowed.
Despite the discussed conceptual and methodological concerns,
we considered conducting a meta-analysis appropriate, especially
for the comparison of antidepressant medication versus tablet
placebo. However, sensitivity analyses addressed differences in
risk of bias between studies, and found no significant differences
between medication and placebo regarding the primary outcome
rate of relapse/recurrence when only studies with low risk of
bias were included. Heterogeneity was planned to be addressed
through subgroup and meta-regression analyses but, due to the
low number of studies included, we were only able to discuss
differences between studies on a descriptive level. In general, for
the majority of comparisons we had to describe the results based
on one single study, not being able to report pooled results.
This review used two primary outcomes, rate of relapse/recurrence
and rate of overall dropout due to other reasons than relapse/
recurrence. Most of the studies reported on both outcomes
separately. Still, there is open discussion if both outcomes overlap
conceptually in continuation and maintenance treatment studies.
For example, in Harrison 1986, all participants of the placebo group
relapsed, resulting in zero dropouts reported during treatment
as participants simply had "no chance" for dropping out due
to relapsing before, possibly overestimating the acceptance of
placebo treatment.
Due to the low number of included studies, we were unable to
undertake all planned subgroup and sensitivity analyses. However,
in future versions of this review, differences between subgroups
should be tested formally (Bucher 1997; Deeks 2008; Song 2003),
and all meta-regression analyses should be performed using the
restricted maximum likelihood estimate method, a recommended
random-effects approach that accounts for residual between-trial
heterogeneity (Thompson 1999).
Continuation and maintenance treatment studies are usually
performed as complex studies, that is, studies with different
treatment phases (acute, continuation, and maintenance
treatment). Criteria and procedures of transition from one into
the next phase differed between studies: some studies defined
response, some remission as an eligibility criterion for the next
phase, including different definitions of response and remission
(see above). Some studies did not rerandomize participants when
entering the new phase (especially concerning the transition from
acute to continuation treatment). Other studies rerandomized
responders from one treatment arm to a different treatment arm
in the next phase, for example Klein 2004 randomized continuation
phase responders of CBASP to CBASP or assessment only in
the maintenance phase. These different procedures complicate
the comparability between different studies. Moreover, studies
mostly described different treatment phases, resulting in partly
overlapping patient groups included in different analyses.
As persistent depression is a chronic condition, relapses or
recurrences are common in this population. Longer treatment
durations (i.e. longer observation periods) probably increase the
chance to observe relapses or recurrences, this must be kept in
mind when comparing the results of different studies with varying
treatment durations.
Concerning data analysis, there is no widely accepted consensus on
how to deal with missing data in meta-analysis when primary data
are not available. In acute-phase studies, researchers can replace
missing values with methods such as LOCF, if study authors do not
report adequate ITT analyses. However, in the case of continuation
and maintenance studies, we assume that LOCF would produce
rather optimistic instead of conservative estimates (see above)
due to its concept of stability of measures over time (Shih 2002).
Thus, we had to deal with the available data sets. However,
percentages of missing data were low: data on overall dropout rates
were complete, the percentage of missing data concerning other
outcomes ranged between 0% and 10%.
Agreements and disagreements with other studies or
reviews
To our knowledge, this is the first review evaluating the
effectiveness of continuation and maintenance treatments in
people with PDD.
A previous review investigated the efficacy and acceptability
of acute treatments in PDD by applying network meta-analytic
methods, showing that several antidepressant medications were
superior to placebo, and that several evidence-based treatments
exist (Kriston 2014). Due to the small number of included studies in
our review, comparisons between different antidepressants could
not systematically be investigated.
In line with the review of von Wolff 2012 on acute treatment in
persistent depression, our review could also not provide a clear
superiority of combined treatments compared to pharmacological
monotherapy.
Regarding continuation and maintenance studies, Wilkinson
2016 evaluated treatments for older people with depressive
disorders. This updated Cochrane Review identified seven studies
of which six compared continued or maintained antidepressant
medication with placebo, favouring antidepressants regarding
relapse/recurrence at 12 months, but showing no significant
differences between treatment arms at six or 24 months' follow-
up. Although this result is in line with our result for this comparison
and outcome, Wilkinson downgraded the level of evidence to low
(GRADE) compared to the GRADE rating of moderate level evidence
in our review. Like in our review, Wilkinson 2016 included just
two studies involving psychological treatment, and data reported
on this as well as combined treatments were too few to draw
conclusions.
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Regarding long-term effects of psychological treatments, Vittengl
2007 conducted a meta-analysis on effects of acute and continued
cognitive therapies CTs in depression. They found high relapse and
recurrence rates (29% within one year and 54% within two years)
for participants discontinuing aRer acute CT. Those participants
continuing CT had significantly fewer relapses and recurrences
compared to active controls (e.g. receiving pharmacotherapy)
at follow-up (10 to 255 weeks aRer end of continuation-phase
treatment), with relapse/recurrence rates of 42% (continued
CT) and 61% (active controls) over 114 weeks on average. In
comparison, rates of relapse/recurrence were similar at end of (20
to 52 weeks') continuation phase for both CT and other active
treatments, with relapse/recurrence rates of 10% (continued CT)
and 22% (active controls) over 27 weeks on average. Although
the results of Vittengl 2007 are encouraging to consider continued
pharmacotherapy or psychotherapy (or both) in depression
treatment, the analyses were based on only five to eight studies.
Guidi 2016 conducted a meta-analysis on the sequential integration
of pharmacotherapy and psychotherapy in major depressive
disorder, that is participants received pharmacotherapy in
the acute phase and psychotherapy in the residual phase.
Receiving cognitive-behavioural therapy (CBT) during continuation
of antidepressant drugs was superior to antidepressants alone
or TAU. Further, participants receiving CBT who had medication
tapered and discontinued were significantly less likely to relapse
compared to clinical management or continued pharmacotherapy.
These analyses were based on 13 studies.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The comparison of antidepressant medication versus placebo
showed coherent results based on five studies favouring
pharmacotherapy as an effective continuation and maintenance
treatment for participants with persistent depressive disorder
(PDD) compared to tablet placebo regarding relapse/recurrence.
However, the quality of evidence was rated moderate and
sensitivity analyses showed that the primary outcome (rate of
relapse/recurrence) did not reach significance when only including
studies with low risk of bias.
On this basis, it cannot be concluded with certainty that continued
or maintained pharmacotherapy (or both) with the reviewed
antidepressant agents is a robust treatment for preventing relapse
and recurrence in people with PDD. As long-term follow-up data
were not available in most of the studies, this review cannot draw
any conclusions about an appropriate duration of antidepressant
medication intake, or when to taper off or stop medication. Studies
in this review predominantly used tapering down of medication
following an a priori-defined scheme, and this is the likely approach
in clinical practice.
Moreover, in two of the five studies reporting a benefit from
antidepressant medication compared to placebo, about half of
the sample size had ongoing psychotherapy in addition to study
treatment. Thus, it is unclear if the individual course of the analyzed
participants is only attributable to the medication provided by the
study, or also to the parallel psychotherapy treatment. This might
be an indication that people with PDD prefer a combined treatment
in clinical practice anyway.
For all other planned comparisons the body of evidence with mostly
just one or two studies providing too little data to draw final
conclusions about recommendations for other types of treatment.
For the type of antidepressant medication as well as distinct
treatment options for specific patient populations (e.g. subtype of
persistent depression), the reported data of the included studies
were too few to draw final conclusions or recommendations. Even
concerning the comparison of antidepressants versus placebo,
meta-regression or subgroup analyses were not possible due to
the small number of eligible studies. Also, all included studies
were conducted in the US and were published between 1986 and
2004. Thus, differences between cultures and healthcare systems,
as well as current developments regarding recommendations of
clinical guidelines are not covered by the studies selected for this
review. Conclusions and recommendations of this review should be
interpreted on this background.
Implications for research
The lack of studies on continuation and maintenance treatments
in people with persistent depression emphasizes the need for
further primary studies – especially on psychological and combined
treatments. The results of Vittengl 2007 suggest that long-term
psychotherapy is effective in depression in general, emphasizing
the need for verification the transferability of these results for the
population of people with persistent depression. Moreover, studies
should also focus on treating older adults who also experience
persistent forms of depression, and who might respond differently
(Wilkinson 2016).
Further studies should assess health-related quality of life as well as
adverse events. Lack of reporting (consistently) on adverse events
is also a common problem in studies on acute treatment of PDD,
especially in psychotherapeutic studies (Meister 2016). Generally,
psychotherapeutic studies fail to report on adverse events
(Lilienfeld 2007; Nutt 2008). Additionally, further studies should
address follow-up evaluations. Comparing continuing treatment to
stopping treatment in the long run is necessary to draw conclusions
on the recommendable duration of continuation and maintenance
treatments. Moreover, cost-effectiveness analyses are important
to compare the relative costs and effects of different treatments,
which we consider especially relevant in the context of long-term
treatments.
People with persistent forms of depression are likely to have a long
duration of illness including a complex treatment history. Although
it might be difficult to assess those aspects in detail in retrospect, it
seems highly relevant to take previous treatments and their effects
into account when organizing further treatments. In this regard,
there might be a conceptual overlap between participants who
are treatment resistant and participants showing persistent forms
of depression. Future research should try to differentiate what
type of treatments are effective dependent on previous treatments,
especially in participants with rather long treatment histories. This
also includes investigating the impact of comorbidities and their
treatments as persistent forms of depression are associated with
increased comorbidity (Arnow 2003; Gilmer 2005).
For this review, we decided to only include studies reporting
on clear response criteria between treatment phases, that is,
only responders were allowed to continue treatment as this
reflects the current definition of continuation and maintenance
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treatments (Frank 1991; NICE 2010). As a consequence, we had
to exclude some well-performed studies evaluating (acute) long-
term treatments not following these strict definitions. However,
those long-term studies investigated treatments that changed
regarding frequency and length over time, similar to studies
we defined as continuation and maintenance treatments. This
probably reflects clinical practice as it is likely that there is oRen
no clear distinction between long-term acute treatment on the
one side and continuation and maintenance treatment on the
other side. Nevertheless, for conducting research and ensuring
the comparability of study results, we recommend standardized
procedures. First, assessing and reporting response, remission, and
recovery data at the end of the intervention (or the intervention
phase). Second, defining whether or not participants receive
further treatment and the reasons for it. Third, defining the
frequency, duration, and contents of each treatment phase, and
whether or not those aspects change between treatment phases.
As there is broad evidence on depression treatments on the
one hand and a lack of studies fulfilling the inclusion criteria of
this review on the other hand, clear diagnostic procedures as
well as clear reporting concerning the persistence of depressive
symptoms is necessary. It is reasonable that several excluded
studies also examined participants with PDD, which could have
been analyzed here if data on this subgroup were reported.
The lack of reporting on this specific diagnosis reflects the fact
that chronic major depression and recurrent depression without
full interepisode remission may be designated as "(recurrent)
major depression" in Diagnostic and Statistical Manual of Mental
Disorders – 4th Edition (DSM-IV) and International Classification
of Diseases 10th Revision (ICD-10), ignoring the persistence of
depressive symptoms. However, the new category "persistent
depressive disorder" implemented in Diagnostic and Statistical
Manual of Mental Disorders – 5th Edition (DSM-5) (duration of at
least two years) increases the likelihood of a precise diagnosis
concerning persistent symptoms.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Design: RCT
Phases: acute (12 weeks), continuation (16 weeks), maintenance (52 weeks)
Comparison groups: nefazodone vs placebo
Funded by: Bristol-Myers Squibb
Participants Number of participants randomized (NRCT: number of participants included): 160
Criteria for relapse/recurrence: "If depressive symptoms began to emerge, as evidenced by a HAM-D-24
score of 16 or greater, another evaluation was scheduled within 2 weeks. Evaluations continued every
2 weeks until either the symptoms subsided or recurrence criteria were met. Recurrence was defined
as a HAM-D-24 score of 16 or greater, together with a diagnosis of MDD as determined from a DSM-IV
MDD checklist administered by the independent evaluator, on two consecutive visits. At the second of
these visits, the recurrence also needed confirmation by each site's senior investigator based on a clini-
cal interview. In addition, because some patients had elevated HAM-D-24 scores but did not meet MDD
criteria, or discontinued before the confirmatory visit, a committee of senior investigators conducted
a blinded review of all patient data at the end of the study. Recurrence was declared if there was con-
sensus among the committee that an episode of MDD had occurred. The committee also indicated the
date of onset of the recurrence. The final definition of time-to-recurrence was based on the first recur-
rence declared by either one of the two methods to define recurrence." (p. 809)
Age distribution in sample (mean): nefazodone: 44.4 (SD 11.1), placebo: 44.1 (SD 8.4)
Sex distribution in sample (% women): nefazodone 69.7; placebo 65.5
Diagnoses in sample: nefazodone: 34.2% chronic major depressive disorder, 36.8% double depression,
29.0% recurrent depressive disorder without complete remission between episodes; placebo: 28.6%
chronic major depressive disorder, 42.9% double depression, 28.6% recurrent depressive disorder
without complete remission between episodes
Depression severity at continuation/maintenance baseline (mean): HAM-D-24 nefazodone: 5.9 (SD 4.4);
placebo: 5.6 (SD 4.0)
Age of onset (mean): nefazodone: 24.1 (SD 13.3) years; placebo: 27.7 (SD 12.7) years
Length current/last major episode (mean): nefazodone: 100.8 (SD 129.6) months; placebo: 87.6 (SD
90.0) months
Interventions Maintenance treatment (52 weeks)
Nefazodone (participants = 76)
Name (class and type): nefazodone (SNDRI)
Planned dosage of drug: 300–600 mg/day
Dosage of drug (mean): 485.9 (SD 115.6) mg/day
Placebo (participants = 84)
Gelenberg 2003 
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Name (class and type): placebo
Planned dosage of placebo: NR
Dosage of placebo (mean): 504.0 (SD 115.9) mg/day
Notes: for all medication visits, any formal psychotherapeutic interventions were proscribed. Partici-
pants in the placebo arm received identical (but inactive) tablets without any tapering down between




Dropout due to adverse events
Notes Probably conflict of interest because of funding.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information.
Allocation concealment
(selection bias)





Low risk Double-blind comparison: participants assigned to placebo received appar-
ently identical, inactive tablets.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary dependent measure was the 24-item HAM-D, which was rated by




Low risk Low number of missing data, main outcomes seem to be reported for all par-
ticipants, see statistical methods. (p. 809)
Selective reporting (re-
porting bias)
Unclear risk Unclear, no information on the measures in the maintenance phase, but rele-
vant outcomes (HAM-D, recurrence, adverse events) were reported, no study
protocol.
Other bias High risk Insufficient treatment adherence: the medication doses were within the
planned range, no laboratory tests are reported.
Allegiance bias/conflict of interest: supported by grants from Bristol-Myers
Squibb.
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Phases: continuation treatment (26.1 weeks) after response to phenelzine treatment
Comparison groups: phenelzine vs placebo
Funded by: probably internal funding by the authors' institution, no information given
Participants Number of participants randomized (NRCT: number of participants included): 12
Criteria for relapse/recurrence: "Patients were considered to have relapsed and were withdrawn from
the protocol if they scored 3 or more on the CGI for 2 consecutive weeks. Patients received a score of 3
on the CGI only if they had a clear recurrence of depressive symptoms." (p. 347)
Age distribution in sample: unclear
Sex distribution in sample (% women): 83.3
Diagnoses in sample: phenelzine: 20.0% dysthymia, 80.0% double depression; placebo: 58.0% dys-
thymia, 42.0% double depression
Depression severity at continuation/maintenance baseline (mean): HAM-D phenelzine: 1.8 (SD 1.3);
placebo: 4.4 (SD 3.9)
Age of onset: unclear
Length current/last major episode in months: unclear
Interventions Continuation treatment (26.1 weeks)
Phenelzine (participants = 5)
Name (class and type): phenelzine (MAOI)
Planned dosage of drug: unclear
Dosage of drug (mean): 51.0 (SD 7.4) mg/day
Placebo (participants = 7)
Name (class and type): tablet placebo
Planned dosage of placebo: NR
Dosage of placebo: NR
Notes: the placebo group discontinued phenelzine treatment over 14 days by tapering the daily dose





Dropout due to adverse event
Experiencing any adverse event (no data available for the placebo group)
Serious adverse events (no data available for the placebo group)
Notes After relapse, participants were treated openly as clinically indicated.
Risk of bias
Harrison 1986  (Continued)
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)





Low risk Quote: "The double blind condition was maintained by providing individual
daily medication packets in which the number of tablets was kept constant by
substituting matching placebo." (pp. 346–7)
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk No missing data
Selective reporting (re-
porting bias)
Unclear risk No study protocol
Other bias Unclear risk Insufficient treatment adherence: no information on treatment adherence.
Allegiance bias/conflict of interest: no information about funding/possible
conflict of interest.
Attention bias: no indication for attention bias, all participants in the placebo





Phases: acute (8 weeks), continuation (16 weeks)
Comparison groups: fluoxetine vs fluoxetine + group psychotherapy
Funded by: grant from Eli Lilly Company.
Participants Number of participants randomized (NRCT: number of participants included): 40
Criteria for relapse/recurrence: not available
Age distribution in sample (mean): 45.1 (SD 9.8) years
Sex distribution in sample (% women): 50
Diagnoses in sample: 100% dysthymia
Depression severity at continuation/maintenance baseline (mean): HAM-D 21: fluoxetine: 7.8 (SD 4.7);
combination: 6.2 (SD 4.9)
Age of onset: unclear
Length current/last major episode in months: unclear
Hellerstein 2001 
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Interventions Continuation treatment (16 weeks)
Fluoxetine (participants = 18)
Name (class and type): fluoxetine (SSRI)
Planned dosage of drug: 20–80 mg/day
Dosage of drug (mean): 38.8 (SD 18.9) mg/day
Combination (participants = 19)
Name (class and type): fluoxetine (SSRI) + group psychotherapy (CT/IPT)
Planned number of sessions + dosage of drug: 16 sessions + 20–80 mg/day
Dosage of drug (mean): 37.4 (SD 17.3) mg/day
Notes: participants were not allowed to currently undergo another psychotherapy. In the medication
group, psychiatrists were instructed not to engage in psychotherapy, counselling, or supportive inter-
ventions.
Outcomes HAM-D-21 mean (end of intervention and follow-up)
Dropout any
SWLS (end of intervention and follow-up)
Notes Possibly conflict of interest (funded by Eli Lilly); discrepant information given in text vs tables; some-
times also unclear/discrepant: information given in text itself; treatment/group therapy = CIGP-CD
manual, which is not classified by Cochrane.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)





High risk Psychotherapy trial, no blinding possible.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk LOCF method for physician rated scales: 7/35 (20%) dropout at follow-up




Unclear risk No existing study protocol.
Other bias High risk Quote: "Insufficient treatment adherence: Sessions were audiotaped and re-
viewed in weekly supervision meetings for adherence to the manual." (pp. 96–
7)
Hellerstein 2001  (Continued)
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Allegiance bias/conflict of interest: financed by pharmaceutical company, but
unclear/no further information.
Attention bias: more attention in the combination group as this group also re-
ceived psychotherapy.
Other: very likely that randomization was before acute treatment, but it was
not described clearly.





Phases: acute (12 weeks), continuation (16 weeks), maintenance (76 weeks)
Comparison groups: sertraline vs placebo
Funded by: grant from Pfizer (NY)
Participants Number of participants randomized (NRCT: number of participants included): 161
Criteria for relapse/recurrence: recurrence: DSM-III-R criteria for major depression for ≥ 3 weeks; CGI
severity score of ≥ 4 (at least moderate severity); CGI improvement score ≥ 3 (minimally improved or
less); and an increase in HAM-D score ≥ 4 points higher than the maintenance baseline; next visit 1 week
later in total ≥ 4 weeks of clinical worsening; additionally: senior investigator supporting diagnosis/re-
currence. (pp. 1666–7)
Age distribution in sample (mean): sertraline: 40.8 (SD 9.0) years; placebo: 42.4 (SD 9.7) years
Sex distribution in sample (% women): sertraline: 62.3; placebo: 69.0
Diagnoses in sample: sertraline: 52.0% chronic major depressive disorder, 48.0% double depression;
placebo: 43.0% chronic major depressive disorder, 57.0% double depression
Depression severity at continuation/maintenance baseline (mean): sertraline: 5.5 (SD 4.2); placebo: 6.3
(SD 3.7)
Age of onset (mean): sertraline: 24.9 (SD 11.2) years; placebo: 25.7 (SD 12.5) years
Length current/last major episode (mean): sertraline: 88.2 (SD 121.7) months; placebo: 54.9 (SD 80.8)
months
Interventions Maintenance treatment (76 weeks)
Sertraline (participants = 77)
Name (class and type): sertraline (SSRI)
Planned dosage of drug: 50–200 mg/day
Dosage of drug (mean): 146.1 mg/day
Placebo (participants = 84)
Name (class and type): placebo tablets
Planned dosage of placebo: unclear
Dosage of placebo (mean): 3.4 tablets/day
Keller 1998b 
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Cochrane Database of Systematic Reviews
Notes: participants in the placebo arm tapered sertraline by 50 mg reduction per week as placebo sub-
stitution.





Dropout due to adverse event
Experiencing any adverse event
Notes Probably conflict of interest because of funding.
They used 2 different criteria for relapse/recurrence, we extracted the stricter one; therefore, maybe
less relapse observed than actual happened, in combination with numerous of dropouts with possible
bias of results.
"Patients meeting recurrence criteria could continue in the study if both patient and study physician
agreed that no change in the study medication was indicated at that time. Instead, an increase in dai-
ly dose was undertaken at a rate of 50mg/week up to the maximum daily dose of 200mg of sertraline
hydrochloride. A similar double-blind titration was also used for patients receiving placebo treatmen-
t." (further details see p. 1667)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)






Quote: "To maintain blinding, this group of patients continued (as a parallel
but non-randomised group) receiving imipramine during subsequent contin-
uation and maintenance phases… The integrity of the study's double-blind
component was not compromised." (p. 1666)
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk 70% dropout in the placebo group. The data were replaced by the LOCF -
method (i.e. 70% of data replaced by last observation point, the participant's
condition was probably better at this earlier time).
Selective reporting (re-
porting bias)
Unclear risk No information
Other bias High risk Insufficient treatment adherence: no information.
Allegiance bias/conflict of interest: whole study financed by Pfizer.
Keller 1998b  (Continued)
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Attention bias: most likely, each treatment group gained same attention (as





Phases: acute (12 weeks), continuation (16 weeks), maintenance (52 weeks)
Comparison groups: CBASP vs assessment only
Funded by: Bristol-Myers Squibb
Participants Number of participants randomized (NRCT: number of participants included): 82
Criteria for relapse/recurrence: "Recurrence was defined in the protocol as a HRSD-24 [HAM-D] score
of 16 or greater on two consecutive visits and a diagnosis of MDD as determined from a DSM–IV MDD
checklist administered by the independent evaluator. At the second of these visits, the recurrence also
needed confirmation by the site's senior investigator on the basis of a clinical interview." (p. 683)
Age distribution in sample (mean): CBASP: 44.2 (SD 11.7) years; assessment only: 46.0 (SD 11.1) years
Sex distribution in sample (% women): CBASP: 81.0; assessment only: 52.5
Diagnoses in sample: CBASP: 50.0% chronic major depressive disorder, 26.2% double depression,
23.8% recurrent depressive disorder with incomplete remission between episodes; assessment only:
60.0% chronic major depressive disorder, 20.0% double depression, 20.0% recurrent depressive disor-
der with incomplete remission between episodes
Depression severity at continuation/maintenance baseline (mean): HAM-D-24: CBASP: 6.6 (SD 3.8); as-
sessment only: 6.2 (SD 4.4)
Age of onset (mean): CBASP: 27.0 (SD 12.4) years; assessment only: 29.5 (SD 13.5) years
Length current/last major episode in months (mean): CBASP: 92.4 (SD 115.2); assessment only: 85.2 (SD
122.4)
Interventions Maintenance treatment (52 weeks)
Name (class and type): CBASP
Planned number of sessions: 13
Number of sessions (mean): 11.1 (SD 3.8)
Name (class and type): assessment only
Planned number of sessions: 13
Number of sessions: unclear





Notes Probably conflict of interest because of funding.
Klein 2004 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)





High risk As CBASP was compared to assessment only, blinding of participants was not
possible.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "The primary outcome measure throughout all phases of the study was
the HRSD-24, which was administered by certified rates who were unaware
of patient's treatment condition. Patients in the CBASP condition were also
seen by the independent evaluator every 4 weeks but did not receive an hono-
rarium. All patients were reminded at each visit not to mention anything that
might reveal their treatment condition to the independent evaluator. If pa-
tients had questions or concerns about the study, they were instructed to raise
them with the project coordinator rather than the independent evaluator. In
the rare instances that the blind was broken, the patient was seen by a differ-
ent independent evaluator at subsequent visits. In both conditions, all psy-





Low risk Quote: "We compared time to recurrence between the CBASP and assessment
only groups using survival analysis. Patients who failed to complete the main-
tenance phase were included in these analyses using all available data up to
the time of exiting the study." (p. 684)
Selective reporting (re-
porting bias)
Unclear risk Study protocol only described outcome measurements for the acute phase.
Other bias Low risk Insufficient treatment adherence. Quote: "Sessions were videotaped and re-
viewed weekly–biweekly by the site supervisor or James P. McCullough to as-
sess adherence to the treatment procedures. Adherence was assessed using
a rating scale described in McCullough (2000). When non-adherence was iden-
tified, it was immediately discussed with the therapist and efforts at remedia-
tion were provided." (p. 683)
Allegiance bias/conflict of interest: some authors were well-known CBASP
therapists (e.g. J McCullough), but there were also other authors; interests
were balanced across authors.
Attention bias: in both conditions, participants saw the therapist or project co-
ordinator every 4 weeks. The project co-ordinator provided them with some





Phases: acute (6–10 weeks), continuation (16–20 weeks), maintenance (104.4 weeks)
Kocsis 1995 
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Comparison groups: imipramine vs desipramine
Funded by: no information
Participants Number of participants randomized (NRCT: number of participants included): 73
Criteria for relapse/recurrence: no information; this outcome was not addressed.
Age distribution in sample (mean): 36.0 (SD 10.0) years
Sex distribution in sample (% women): 64.1
Diagnoses in sample: 37.0% dysthymia, 63.0% double depression
Depression severity at continuation/maintenance baseline: unclear
Age of onset: unclear
Length current/last major episode in months: unclear
Interventions Continuation treatment (16–20 weeks)
Imipramine (participants = 23)
Name (class and type): imipramine (TCA)
Planned dosage of drug: 300 mg/day
Dosage of drug: unclear
Sertraline (participants = 50)
Name (class and type): desipramine (TCA)
Planned dosage of drug: 200 mg/day
Dosage of drug (mean): 232 (SD 72) mg/day
Notes: "Patients were allowed to remain in stable long-term psychotherapy during the study but were
not allowed to enter into new psychotherapy arrangements." (p. 214) No data provided about the per-
centage of participants receiving parallel psychotherapy. "Concomitant psychotropic medications
were proscribed." (p. 214)
Outcomes Dropout any
Dropout due to adverse event
Notes There were 3 different treatment arms in the acute treatment, but it was unclear how participants were
allocated to the different treatment arms, e.g. if there were randomized. Additionally, the rationale of
the acute treatment was unclear (e.g. some participants received medication on a double blind and





Phases: acute (10 weeks), continuation (16 weeks), maintenance (104.4 weeks)
Comparison groups: desipramine vs placebo
Funded by: grant from the National Institute of Mental Health
Kocsis 1996 
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)
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Participants Number of participants randomized (NRCT: number of participants included): 53
Criteria for relapse/recurrence: "Suspected relapse occurred when a HAM-D score rose above 12 during
the maintenance phase. Clinicians discussed and encouraged compliance and obtained a plasma drug
level, which was reviewed by a non blind observer who was not involved in the treatment. The non-
blind observer gave instructions or dummy instructions for dosage adjustments. Relapse was defined
as HAM-D scores greater than 12 and GAS scores below 60 on three successive ratings over a period of
4 weeks or at least one rating meeting these criteria and an urgent need for alternative treatment for a
depressive syndrome." (p. 771)
Age distribution in sample (mean): 36.9 (SD 9.6) years
Sex distribution in sample (% women): 57.4
Diagnoses in sample: 10.9% chronic major depressive disorder, 39.5% dysthymia, 49.6% double de-
pression
Depression severity at continuation/maintenance baseline: unclear
Age of onset (mean): 12.6 (SD 6.9) years
Length current/last major episode in months: unclear
Interventions Maintenance treatment (104.4 weeks)
Desipramine (participants = 28)
Name (class and type): desipramine (TCA)
Planned dosage of drug: 75–350 mg/day
Dosage of drug: unclear
Placebo (participants = 25)
Name (class and type): placebo
Planned dosage of drug: participants in the placebo group were tapered by approximately 25% per
week over the month and then received identical placebo at the same dose equivalent for the next 23
months or until relapse.
Dosage of drug: unclear
Notes: participants in the placebo arm were tapered down by 25% per week during the first month
of maintenance treatment followed by receiving identical placebo tablets. Stable psychotherapeutic
treatment was allowed during the study, 39% of participants from the desipramine group and 40% of
participants from the placebo group were in stable psychotherapeutic treatment during the study.
Outcomes Relapse/recurrence
Dropout any
Notes Desipramine (norpramine) and matching placebo were provided by Marion Merrill Dow Inc., Kansas
City, MO.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Kocsis 1996  (Continued)
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Allocation concealment
(selection bias)






Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "A third possible limitation in the present study was the absence of in-
dependent raters. Ratings were done by study clinicians who may have been




Low risk 50/53 (5.7% dropout during maintenance treatment) participants completed ≥




High risk No study protocol available. Quote: "A self-rated measure of social impairment
and function, the Social Adjustment Scale-Self-rated was completed at the be-
ginning and end of each phase of the study." (p. 771) AND: "Subjects were seen
and rated each month during the maintenance phase." (p. 771). Very incom-
plete data in the text/tables (just full vs partial remission and relapse, but no
presentation of clear data about HAM-D, GAS, and SAS-SR).
Other bias Low risk Insufficient treatment adherence: control of plasma drug concentrations.
Allegiance bias/conflict of interest: no indication for conflict of interest.
Attention bias: no differences between the groups. Participants were seen and





Phases: acute (12 weeks), continuation (16 weeks), maintenance (52 weeks)
Comparison groups: nefazodone vs CBASP vs combination
Funded by: Bristol-Myers Squibb
Participants Number of participants randomized (NRCT: number of participants included): 329
Criteria for relapse/recurrence: "Two definitions of relapse were utilized. Any patient who scored high-
er than 15 on the HAM-D was considered at risk for a relapse of MDD. In all such cases, an independent
evaluator completed the DSM-IV criteria checklist for MDD, and if the patient met DSM-IV symptom
criteria, the treating clinician was notified. A confirmatory visit was scheduled within 14 days and the
HAM-D and MDD criteria checklist assessment were repeated. Patients meeting MDD criteria were eval-
uated by an independent senior investigator to confirm relapse. In addition, an investigator could de-
clare a relapse on de facto grounds in the case of an exacerbation of depressive symptomatology with
marked incapacity and clinically significant suicidal ideation, including psychiatric hospitalizations re-
sulting from such exacerbations. Patients not meeting relapse criteria but continuing to score higher
than 15 on the HAM-D were followed every other week until their outcome was clarified." (p. 77)
Age distribution in sample (mean): nefazodone: 43.1 (SD 9.7) years; CBASP: 44.0 (SD 10.8) years; combi-
nation: 44.6 (SD 9.4) years
Sex distribution in sample (% women): nefazodone: 58.7; CBASP: 66.3; combination: 67.8
Kocsis 2003 
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)
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Diagnoses in sample: nefazodone: 32.6% chronic major depressive disorder, 41.3% double depres-
sion, 26.1% recurrent depressive disorder with incomplete remission between episodes; CBASP: 33.7%
chronic major depressive disorder, 46.1% double depression, 20.2% recurrent depressive disorder
with incomplete remission between episodes; combination: 32.2% chronic major depressive disorder,
42.1% double depression, 26.6% recurrent depressive disorder with incomplete remission between
episodes
Depression severity at continuation/maintenance baseline: unclear
Age of onset (mean): nefazodone: 26.3 (SD 13.1) years; CBASP: 28.1 (SD 13.5) years; combination: 27.0
(SD 12.9) years
Length current/last major episode in months (mean): nefazodone: 92.4 (SD 114.0); CBASP: 105.6 (SD
144.0); combination: 99.6 (SD 120.0)
Interventions Continuation treatment (16 weeks)
Nefazodone (participants = 91)
Name (class and type): nefazodone (SNDRI)
Planned dosage of drug: 300–600 mg/day
Dosage of drug (mean): 499 (SD 115) mg/day
CBASP (participants = 88)
Name (class and type): CBASP
Planned number of sessions: 6
Number of sessions (mean): 6 (SD 1)
Combination (participants = 150)
Name (class and type): combination (SNDRI + CBASP)
Planned number of sessions + dosage of drug: 6 sessions + 300–600 mg/day
Number of sessions + dosage of drug (mean): 5.9 (SD 1.1) sessions + 479 (SD 108) mg/day
Notes: "Pharmacotherapists were directed not to provide any psychotherapeutic interventions." (p. 76)
Outcomes Relapse/recurrence
Dropout any






Phases: acute (12 weeks), continuation (16 weeks), maintenance (76 weeks)
Comparison groups: sertraline vs imipramine
Funded by: grant from Pfizer (NY)
Participants Number of participants randomized (NRCT: number of participants included): 386
Koran 2001 
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)
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Criteria for relapse/recurrence: "A full remission of depression was defined as a CGI improvement score
(CGI-I) (Guy, 1976) of 1 or 2 (very much or much improved) and a Hamilton Depression Rating Scale
score (HRSD [HAM-D]) (Hamilton, 1960) ≤ 7. A satisfactory therapeutic response (partial remission) was
defined as a CGI-I ≥2, a HRSD ≤ 15 with a ≥ 50% decrease from baseline, and a CGI severity score (CGI-S)
≤ 3 (i.e. no more than mild depression). A patient whose scores dropped below a 'satisfactory therapeu-
tic response' for a 4-week period was considered relapsed." (p. 29)
Age distribution in sample (mean): sertraline: 40.2 (SD 9.7) years; imipramine: 43.1 (SD 9.6) years
Sex distribution in sample (% women): sertraline: 68.2; imipramine: 57.1
Diagnoses in sample: sertraline: 49.0% chronic major depressive disorder, 51.0% double depression;
imipramine: 45.0% chronic major depressive disorder, 55.0% double depression
Depression severity at continuation/maintenance baseline (mean): sertraline: 6.7 (SD 3.7); imipramine:
6.9 (SD 3.5)
Mean age of onset: unclear
Length current/last major episode (mean): sertraline: 73.2 (SD 98.4) months; imipramine: 76.8 (SD
114.0) months
Interventions Continuation treatment (16 weeks)
Sertraline (participants = 239)
Name (class and type): sertraline (SSRI)
Planned dosage of drug: 50–200 mg/day
Dosage of drug (mean): 149 (SD 55) mg/day
Imipramine (participants = 147)
Name (class and type): imipramine (TCA)
Planned dosage of drug: 50–300 mg/day
Dosage of drug: 227 (SD 73) mg/day
Notes: "Psychotherapy was not allowed during the study unless it had started at least 3 months before
acute phase randomisation and continued throughout all stages of the study without change." (p. 28)





Dropout due to adverse event
Notes Probably conflict of interest because of funding (authors = members of industry who financed study).
Further randomized comparison on maintenance treatment of the sertraline group with placebo in the
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Phases: acute (10–12 weeks), continuation (16 weeks), maintenance (104.4 weeks)
Comparison groups: desipramine vs placebo
Funded by: supported by grant R01-MH37103 from the National Institute of Mental Health and from a
fund established in the New York Community Trust by DeWitt-Wallace.
Participants Number of participants randomized (NRCT: number of participants included): 27
Criteria for relapse/recurrence: "Recurrence was defined as HAM-D scores > 12 and GAS scores < 60 on
three successive ratings over a period of 4 weeks or at least one rating meeting these criteria and an ur-
gent need for alternative treatment for recurrence of depressive symptoms." (p. 233)
Age distribution in sample (mean): desipramine: 34.4 (SD 9.6) years; placebo: 39.0 (SD 11.2) years
Sex distribution in sample (% women): desipramine: 43.0; placebo: 46.0
Diagnoses in sample: 100% dysthymia
Depression severity at continuation/maintenance baseline (mean): desipramine: 3.1 (SD 2.5); placebo:
3.9 (SD 5.2)
Age of onset (mean): desipramine: 14.5 (SD 10.4) years; placebo: 12.3 (SD 8.0) years
Length current/last major episode: unclear
Interventions Maintenance treatment (104.4 weeks)
Desipramine (participants = 14)
Name (class and type): desipramine (TCA)
Dosage of drug: unclear
Dosage of drug (mean): 223 (SD 90) mg/day
Placebo (participants = 13)
Name (class and type): placebo
Planned dosage of placebo: unclear
Dosage of placebo (mean): 240 (SD 60) mg/day (dummy dosage)
Notes: participants in the placebo arm were tapered down by 25% per week during the first month
of maintenance treatment followed by receiving identical placebo tablets. 43% of participants from
the desipramine group and 38% of participants from the placebo group were in stable long-term psy-
chotherapy during the study, a non-significant difference.
Outcomes Relapse/recurrence
Notes Analysis of the dysthymic subgroup of Kocsis et al. 1996 and some additional participants with dys-
thymia.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)
Unclear risk No information
Miller 2001  (Continued)
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Low risk Double-blind maintenance phase
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "Ratings were done by study clinicians who were blinded to treatment
assignment, but may have guessed the maintenance treatment based on side




Low risk No missing outcome data for the available outcome.
Selective reporting (re-
porting bias)
High risk No study protocol available, only recurrence rates were reported, HAM-D, GAS,
and SASR was also measured.
Other bias Low risk Insufficient treatment adherence: serum level control.
Allegiance bias/conflict of interest: no indication for a conflict of interest.
Attention bias: same approach in both conditions (quote: "monthly 20–30
minute appointments to monitor clinical status and manage side effects. Ther-
apists provided support and encouragement, and medication compliance was
discussed throughout." (p. 232)
Miller 2001  (Continued)
CBASP: Cognitive Behavioral Analysis System of Psychotherapy; CGI: Clinical Global Impression; CIGP-CD: Cognitive-Interpersonal Group
Psychotherapy for Chronic Depression; CT: cognitive therapy; DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders 3rd Edition
– Revised; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders 4th Edition; GAS: Global Assessment Scale; HAM-D: Hamilton
Depression Rating Scale; HRSD: Hamilton Rating Scale for Depression (also known as HAM-D); IPT: interpersonal psychotherapy; LOCF:
last observation carried forward; MAOI: monoamine oxidase inhibitor; MDD: major depressive episode; NR: not reported; NRCT: non-
randomized controlled trial; Q-LES-Q: Quality of Life Enjoyment and Satisfaction Questionnaire; RCT: randomized controlled trial; SAS-SR:
Social Adjustment Scale – Self-Report; SD: standard deviation; SF-36: 36-item Short-Form Health Survey; SNDRI: selective noradrenaline-
dopamine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; SWLS: Satisfaction With Life Scale; TCA: tricyclic antidepressant.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Bockting 2005 Included participants were remitted, some with and some without treatment. The interval between
acute and continuation treatment was too long in some cases (> 1 year).
Fava 2004 Participants did not meet the criteria of persistent depression (duration < 2 years).
Franchini 1997 Participants did not meet the criteria of persistent depression (duration < 2 years).
Frank 2007 Participants did not meet the criteria of persistent depression (duration < 2 years).
Hamidian 2013 No response during acute treatment required for entering MBCT.
Hellerstein 1994 Acute treatment with long-term follow-up
Hellerstein 2015 No comparator (pilot study)
Hellerstein 2017 No response during acute treatment required to enter continuation trial.
Holländare 2013 Participants did not meet the criteria of persistent depression (duration < 2 years).
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Study Reason for exclusion
Huijbers 2015 Participants did not meet the criteria of persistent depression (duration < 2 years).
Jarrett 2013 Participants did not meet the criteria of persistent depression (duration < 2 years); just 5% partici-
pants with double depression.
Kok 2015 Participants did not meet the criteria of persistent depression (duration < 2 years); duration of
episode maximum 2 years for being eligible.
Michalak 2015 No response during acute treatment required for entering MBCT.
Murray 2010 No response during acute treatment required to enter intervention.
Petersen 2010 Partly meeting criteria for a PDD diagnosis; exact amount of persistent depressed participants un-
clear.
Schramm 2017 No response during acute treatment required to enter continuation trial.
Thase 2001 < 80% of participants with a PDD diagnosis.
van Aalderen 2015 Participants did not meet the criteria of persistent depression (duration < 2 years).
Wiersma 2008 No response during acute treatment required to enter continuation trial.
MBCT: mindfulness-based cognitive therapy; PDD: persistent depressive disorder.
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Design: RCT
Phases: continuation (approximately 26 weeks)
Comparison groups: T-CT (telephone-delivered cognitive-behavioral continuation therapy) vs usual
care
Funded by: University of Zurich
Participants Estimated enrolment: 218
Ages: 18 years to 75 years
Sexes Eligible for Study: All
Diagnoses: Recurrent major depressive disorder or chronic/persistent depressive disorder based
on the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Interventions Continuation treatment (approximately 26 weeks)
Behavioral: telephone-administered continuation therapy
The intervention includes eight therapy sessions of approximately 50 minutes duration delivered
over the telephone by trained psychotherapists over a time period of six months. The intervention
is grounded in the principles of psychological continuation therapy and relapse prevention, and in-
cludes strategies such as transferring helpful elements of acute-phase cognitive-behavioral thera-
py for depression to daily life. T-CT is offered in addition to usual care.
Other: Usual care
Usual care without any study-related intervention
NCT03219879 
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)









Cochrane Database of Systematic Reviews
Other Name: Treatment as usual
Outcomes Primary outcome: Relapse of a major depressive episode (time frame: 6 months, 12 months, and 18
months after baseline)
Secondary outcomes:
Well-weeks (time frame: 6 months, 12 months, and 18 months after baseline)
Depressive symptoms (time frame: baseline, 3 months, 6 months, and 12 months after baseline)
Health-related quality of life (time frame: baseline, 3 months, 6 months, and 12 months after base-
line)
Anxiety symptoms (time frame: baseline, 3 months, 6 months, and 12 months after baseline)
Psychosocial functioning (time frame: 6 months and 12 months after baseline)
Cost of health care utilization (time frame: baseline, 6 months, and 12 months after baseline)
Cost-effectiveness (time frame: baseline, 6 months, and 12 months after baseline)
Other Pre-specified Outcome Measures:
T-CT acceptability (time frame: 6 months after baseline)
Treatment satisfaction (time frame: baseline, and 6 months after baseline)
Self-confidence (time frame: baseline, 6 months, and 12 months after baseline)
Physical activity (time frame: baseline, 6 months, and 12 months after baseline)
Self-efficacy for depression self-management (time frame: baseline, 3 months, 6 months, and 12
months after baseline)
Self-management behaviours (time frame: baseline, 3 months, 6 months, and 12 months after
baseline)
Interpersonal emotion regulation skills (time frame: baseline, 6 months, and 12 months after base-
line)
Therapeutic alliance (time frame: baseline, 3 months, and 6 months after baseline)
Notes  
NCT03219879  (Continued)




D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Pharmacological continuation and maintenance therapies versus placebo





Statistical method Effect size
1 Relapse/recurrence 4 383 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.21, 0.79]
2 Dropout due to any reason 4 386 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.39, 2.11]
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Statistical method Effect size
3 Depression severity 3 333 Mean Difference (IV, Random, 95%
CI)
-4.79 [-8.49, -1.09]
4 SF-36 Social Functioning score 1 161 Mean Difference (IV, Random, 95%
CI)
10.80 [3.04, 18.56]
5 SF-36 Emotional Role score 1 161 Mean Difference (IV, Random, 95%
CI)
20.70 [7.43, 33.97]
6 SF-36 Role Physical score 1 161 Mean Difference (IV, Random, 95%
CI)
2.10 [-9.76, 13.96]
7 Dropout due to any type of adverse
event
3 333 Odds Ratio (M-H, Random, 95% CI) 3.53 [0.67, 18.70]
8 Any type of adverse event 1 161 Odds Ratio (M-H, Random, 95% CI) 1.47 [0.70, 3.09]
9 Relapse/recurrence sensitivity analysis 4 360 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.16, 0.89]
 
 
Analysis 1.1.   Comparison 1 Pharmacological continuation and
maintenance therapies versus placebo, Outcome 1 Relapse/recurrence.
Study or subgroup Medication Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gelenberg 2003 20/76 29/84 38.19% 0.76[0.47,1.23]
Harrison 1986 1/5 7/7 14.9% 0.27[0.07,1.08]
Keller 1998b 5/77 19/84 24.08% 0.29[0.11,0.73]
Kocsis 1996 4/27 12/23 22.82% 0.28[0.11,0.76]
   
Total (95% CI) 185 198 100% 0.41[0.21,0.79]
Total events: 30 (Medication), 67 (Placebo)  
Heterogeneity: Tau2=0.23; Chi2=6.48, df=3(P=0.09); I2=53.71%  
Test for overall effect: Z=2.68(P=0.01)  
Favours medication 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.2.   Comparison 1 Pharmacological continuation and maintenance
therapies versus placebo, Outcome 2 Dropout due to any reason.
Study or subgroup Medication Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gelenberg 2003 10/76 23/84 37.79% 0.48[0.24,0.94]
Harrison 1986 2/5 0/7 7.54% 6.67[0.39,114.78]
Keller 1998b 31/77 26/84 44.27% 1.3[0.85,1.98]
Kocsis 1996 1/28 2/25 10.4% 0.45[0.04,4.63]
   
Total (95% CI) 186 200 100% 0.9[0.39,2.11]
Favours medication 1000.01 100.1 1 Favours placebo
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)









Cochrane Database of Systematic Reviews
Study or subgroup Medication Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 44 (Medication), 51 (Placebo)  
Heterogeneity: Tau2=0.38; Chi2=8.29, df=3(P=0.04); I2=63.8%  
Test for overall effect: Z=0.23(P=0.81)  
Favours medication 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.3.   Comparison 1 Pharmacological continuation and
maintenance therapies versus placebo, Outcome 3 Depression severity.
Study or subgroup Medication Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Gelenberg 2003 76 9.6 (9.7) 84 11.7 (9.5) 43.02% -2.1[-5.08,0.88]
Harrison 1986 5 7 (8.5) 7 18 (5.4) 14.48% -11[-19.46,-2.54]
Keller 1998b 77 9.9 (9.2) 84 15.3 (10.5) 42.51% -5.4[-8.44,-2.36]
   
Total *** 158   175   100% -4.79[-8.49,-1.09]
Heterogeneity: Tau2=5.97; Chi2=4.98, df=2(P=0.08); I2=59.85%  
Test for overall effect: Z=2.54(P=0.01)  
Favours medication 10050-100 -50 0 Favours placebo
 
 
Analysis 1.4.   Comparison 1 Pharmacological continuation and maintenance
therapies versus placebo, Outcome 4 SF-36 Social Functioning score.
Study or subgroup Medication Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Keller 1998b 77 80.6 (22) 84 69.8 (28.1) 100% 10.8[3.04,18.56]
   
Total *** 77   84   100% 10.8[3.04,18.56]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.73(P=0.01)  
Favours placebo 10050-100 -50 0 Favours medication
 
 
Analysis 1.5.   Comparison 1 Pharmacological continuation and maintenance
therapies versus placebo, Outcome 5 SF-36 Emotional Role score.
Study or subgroup Medication Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Keller 1998b 77 65.7 (41.8) 84 45 (44.1) 100% 20.7[7.43,33.97]
   
Total *** 77   84   100% 20.7[7.43,33.97]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.06(P=0)  
Favours placebo 10050-100 -50 0 Favours medication
 
 
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)









Cochrane Database of Systematic Reviews
Analysis 1.6.   Comparison 1 Pharmacological continuation and maintenance
therapies versus placebo, Outcome 6 SF-36 Role Physical score.
Study or subgroup Medication Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Keller 1998b 77 74.3 (36.4) 84 72.2 (40.4) 100% 2.1[-9.76,13.96]
   
Total *** 77   84   100% 2.1[-9.76,13.96]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.73)  
Favours placebo 10050-100 -50 0 Favours medication
 
 
Analysis 1.7.   Comparison 1 Pharmacological continuation and maintenance
therapies versus placebo, Outcome 7 Dropout due to any type of adverse event.
Study or subgroup Medication Placebo Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gelenberg 2003 4/76 4/84 47.41% 1.11[0.27,4.61]
Harrison 1986 2/5 0/7 18.95% 10.71[0.4,287.83]
Keller 1998b 8/77 1/84 33.64% 9.62[1.17,78.84]
   
Total (95% CI) 158 175 100% 3.53[0.67,18.7]
Total events: 14 (Medication), 5 (Placebo)  
Heterogeneity: Tau2=1; Chi2=3.69, df=2(P=0.16); I2=45.73%  
Test for overall effect: Z=1.48(P=0.14)  
Favours medication 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.8.   Comparison 1 Pharmacological continuation and maintenance
therapies versus placebo, Outcome 8 Any type of adverse event.
Study or subgroup Medication Placebo Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Keller 1998b 62/77 62/84 100% 1.47[0.7,3.09]
   
Total (95% CI) 77 84 100% 1.47[0.7,3.09]
Total events: 62 (Medication), 62 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.01(P=0.31)  
Favours medication 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.9.   Comparison 1 Pharmacological continuation and maintenance
therapies versus placebo, Outcome 9 Relapse/recurrence sensitivity analysis.
Study or subgroup Medication Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gelenberg 2003 20/76 29/84 41.4% 0.76[0.47,1.23]
Harrison 1986 1/5 7/7 20.73% 0.27[0.07,1.08]
Favours medication 1000.01 100.1 1 Favours placebo
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Study or subgroup Medication Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Keller 1998b 5/77 19/84 30.13% 0.29[0.11,0.73]
Miller 2001 0/14 6/13 7.74% 0.07[0,1.16]
   
Total (95% CI) 172 188 100% 0.38[0.16,0.89]
Total events: 26 (Medication), 61 (Placebo)  
Heterogeneity: Tau2=0.39; Chi2=7.19, df=3(P=0.07); I2=58.3%  
Test for overall effect: Z=2.24(P=0.03)  
Favours medication 1000.01 100.1 1 Favours placebo
 
 
Comparison 2.   Psychological continuation and maintenance therapies versus attention placebo/non-specific
control





Statistical method Effect size
1 Relapse/recurrence 1 82 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.14, 0.93]
2 Dropout due to any reason 1 82 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.41, 1.81]
3 Depression severity 1 82 Mean Difference (IV, Random, 95% CI) -4.00 [-7.05, -0.95]
 
 
Analysis 2.1.   Comparison 2 Psychological continuation and maintenance therapies
versus attention placebo/non-specific control, Outcome 1 Relapse/recurrence.
Study or subgroup Psychotherapy Assess-
ment only
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Klein 2004 5/42 13/40 100% 0.37[0.14,0.93]
   
Total (95% CI) 42 40 100% 0.37[0.14,0.93]
Total events: 5 (Psychotherapy), 13 (Assessment only)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.1(P=0.04)  
Favours psychotherapy 1000.01 100.1 1 Favours assessment only
 
 
Analysis 2.2.   Comparison 2 Psychological continuation and maintenance therapies
versus attention placebo/non-specific control, Outcome 2 Dropout due to any reason.
Study or subgroup Psychotherapy Assess-
ment only
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Klein 2004 10/42 11/40 100% 0.87[0.41,1.81]
   
Total (95% CI) 42 40 100% 0.87[0.41,1.81]
Favours psychotherapy 1000.01 100.1 1 Favours assessment only
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Study or subgroup Psychotherapy Assess-
ment only
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 10 (Psychotherapy), 11 (Assessment only)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.38(P=0.7)  
Favours psychotherapy 1000.01 100.1 1 Favours assessment only
 
 
Analysis 2.3.   Comparison 2 Psychological continuation and maintenance therapies
versus attention placebo/non-specific control, Outcome 3 Depression severity.
Study or subgroup Psychotherapy Assessment only Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Klein 2004 42 6.3 (5.6) 40 10.3 (8.2) 100% -4[-7.05,-0.95]
   
Total *** 42   40   100% -4[-7.05,-0.95]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.57(P=0.01)  
Favours psychotherapy 10050-100 -50 0 Favours assessment only
 
 
Comparison 3.   Psychological continuation and maintenance therapies versus pharmacological continuation and
maintenance therapies





Statistical method Effect size
1 Relapse/recurrence 1 176 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.43, 3.49]
2 Dropout due to any reason 1 179 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.30, 1.03]
 
 
Analysis 3.1.   Comparison 3 Psychological continuation and maintenance therapies versus
pharmacological continuation and maintenance therapies, Outcome 1 Relapse/recurrence.
Study or subgroup Psychotherapy Medication Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kocsis 2003 7/86 6/90 100% 1.22[0.43,3.49]
   
Total (95% CI) 86 90 100% 1.22[0.43,3.49]
Total events: 7 (Psychotherapy), 6 (Medication)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.37(P=0.71)  
Favours psychotherapy 1000.01 100.1 1 Favours medication
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Analysis 3.2.   Comparison 3 Psychological continuation and maintenance therapies versus
pharmacological continuation and maintenance therapies, Outcome 2 Dropout due to any reason.
Study or subgroup Psychotherapy Medication Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kocsis 2003 13/88 24/91 100% 0.56[0.3,1.03]
   
Total (95% CI) 88 91 100% 0.56[0.3,1.03]
Total events: 13 (Psychotherapy), 24 (Medication)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.87(P=0.06)  
Favours psychotherapy 1000.01 100.1 1 Favours medication
 
 
Comparison 4.   Combined psychological and pharmacological continuation and maintenance therapies versus
pharmacological continuation and maintenance therapies alone





Statistical method Effect size
1 Relapse/recurrence 1 238 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.44, 3.44]
2 Dropout due to any reason 2 280 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.90, 2.29]
3 Depression severity 1 39 Mean Difference (IV, Random, 95% CI) 2.8 [0.38, 5.22]
4 Depression severity – follow-up 1 39 Mean Difference (IV, Random, 95% CI) 0.90 [-3.26, 5.06]
5 Health-related quality of life 1 35 Mean Difference (IV, Random, 95% CI) -0.5 [-1.63, 0.63]
6 Health-related quality of life – fol-
low-up
1 33 Mean Difference (IV, Random, 95% CI) 0.60 [-0.56, 1.76]
 
 
Analysis 4.1.   Comparison 4 Combined psychological and pharmacological continuation and maintenance
therapies versus pharmacological continuation and maintenance therapies alone, Outcome 1 Relapse/recurrence.
Study or subgroup Medication Combination Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kocsis 2003 6/90 8/148 100% 1.23[0.44,3.44]
   
Total (95% CI) 90 148 100% 1.23[0.44,3.44]
Total events: 6 (Medication), 8 (Combination)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
Favours medication 1000.01 100.1 1 Favours combination
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Analysis 4.2.   Comparison 4 Combined psychological and pharmacological continuation and maintenance therapies
versus pharmacological continuation and maintenance therapies alone, Outcome 2 Dropout due to any reason.
Study or subgroup Medication Combination Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Hellerstein 2001 2/19 2/20 6.37% 1.05[0.16,6.74]
Kocsis 2003 24/91 27/150 93.63% 1.47[0.9,2.38]
   
Total (95% CI) 110 170 100% 1.43[0.9,2.29]
Total events: 26 (Medication), 29 (Combination)  
Heterogeneity: Tau2=0; Chi2=0.11, df=1(P=0.74); I2=0%  
Test for overall effect: Z=1.51(P=0.13)  
Favours medication 1000.01 100.1 1 Favours combination
 
 
Analysis 4.3.   Comparison 4 Combined psychological and pharmacological continuation and maintenance
therapies versus pharmacological continuation and maintenance therapies alone, Outcome 3 Depression severity.
Study or subgroup Medication Combined
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Hellerstein 2001 19 6 (4) 20 3.2 (3.7) 100% 2.8[0.38,5.22]
   
Total *** 19   20   100% 2.8[0.38,5.22]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.27(P=0.02)  
Favours medication 10050-100 -50 0 Favours combination
 
 
Analysis 4.4.   Comparison 4 Combined psychological and pharmacological continuation and maintenance therapies
versus pharmacological continuation and maintenance therapies alone, Outcome 4 Depression severity – follow-up.
Study or subgroup Medication Combined
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Hellerstein 2001 19 8.2 (7.1) 20 7.3 (6.1) 100% 0.9[-3.26,5.06]
   
Total *** 19   20   100% 0.9[-3.26,5.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.42(P=0.67)  
Favours medication 10050-100 -50 0 Favours combination
 
 
Analysis 4.5.   Comparison 4 Combined psychological and pharmacological continuation and maintenance therapies
versus pharmacological continuation and maintenance therapies alone, Outcome 5 Health-related quality of life.
Study or subgroup Medication Combined
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Hellerstein 2001 17 3.4 (1.7) 18 3.9 (1.7) 100% -0.5[-1.63,0.63]
Favours combination 10050-100 -50 0 Favours medication
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Study or subgroup Medication Combined
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
   
Total *** 17   18   100% -0.5[-1.63,0.63]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.87(P=0.38)  
Favours combination 10050-100 -50 0 Favours medication
 
 
Analysis 4.6.   Comparison 4 Combined psychological and pharmacological
continuation and maintenance therapies versus pharmacological continuation and
maintenance therapies alone, Outcome 6 Health-related quality of life – follow-up.
Study or subgroup Medication Combined
treatment
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Hellerstein 2001 15 3 (1.7) 18 2.4 (1.7) 100% 0.6[-0.56,1.76]
   
Total *** 15   18   100% 0.6[-0.56,1.76]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.01(P=0.31)  
Favours medication 10050-100 -50 0 Favours combination
 
 
Comparison 5.   Combined psychological and pharmacological continuation and maintenance therapies versus
psychotherapeutic continuation and maintenance therapies alone





Statistical method Effect size
1 Relapse/recurrence 1 234 Risk Ratio (M-H, Random, 95% CI) 1.51 [0.57, 4.01]
2 Dropout due to any reason 1 238 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.45, 1.51]
 
 
Analysis 5.1.   Comparison 5 Combined psychological and pharmacological continuation and maintenance therapies
versus psychotherapeutic continuation and maintenance therapies alone, Outcome 1 Relapse/recurrence.
Study or subgroup Psychotherapy Combined
treatment
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kocsis 2003 7/86 8/148 100% 1.51[0.57,4.01]
   
Total (95% CI) 86 148 100% 1.51[0.57,4.01]
Total events: 7 (Psychotherapy), 8 (Combined treatment)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.82(P=0.41)  
Favours psychotherapy 1000.01 100.1 1 Favours combination
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Analysis 5.2.   Comparison 5 Combined psychological and pharmacological continuation and maintenance therapies
versus psychotherapeutic continuation and maintenance therapies alone, Outcome 2 Dropout due to any reason.
Study or subgroup Psychotherapy Combined
treatment
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kocsis 2003 13/88 27/150 100% 0.82[0.45,1.51]
   
Total (95% CI) 88 150 100% 0.82[0.45,1.51]
Total events: 13 (Psychotherapy), 27 (Combined treatment)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.64(P=0.52)  
Favours psychotherapy 1000.01 100.1 1 Favours combination
 
 
Comparison 6.   Imipramine (TCA) versus desipramine (TCA)





Statistical method Effect size
1 Dropout due to any reason 1 73 Risk Ratio (M-H, Random, 95% CI) 4.35 [1.19, 15.87]
2 Dropout due to any type of adverse
event
1 73 Odds Ratio (M-H, Random, 95% CI) 1.49 [0.23, 9.60]
 
 
Analysis 6.1.   Comparison 6 Imipramine (TCA) versus desipramine (TCA), Outcome 1 Dropout due to any reason.
Study or subgroup Imipramine Desipramine Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kocsis 1995 6/23 3/50 100% 4.35[1.19,15.87]
   
Total (95% CI) 23 50 100% 4.35[1.19,15.87]
Total events: 6 (Imipramine), 3 (Desipramine)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.22(P=0.03)  
Favours imipramine 1000.01 100.1 1 Favours desipramine
 
 
Analysis 6.2.   Comparison 6 Imipramine (TCA) versus desipramine
(TCA), Outcome 2 Dropout due to any type of adverse event.
Study or subgroup Imipramine Desipramine Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kocsis 1995 2/23 3/50 100% 1.49[0.23,9.6]
   
Total (95% CI) 23 50 100% 1.49[0.23,9.6]
Total events: 2 (Imipramine), 3 (Desipramine)  
Favours imipramine 1000.01 100.1 1 Favours desipramine
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Study or subgroup Imipramine Desipramine Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.42(P=0.67)  
Favours imipramine 1000.01 100.1 1 Favours desipramine
 
 
Comparison 7.   Imipramine (TCA) versus sertraline (SSRI)





Statistical method Effect size
1 Relapse/recurrence 1 376 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.84, 1.91]
2 Dropout due to any reason 1 386 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.48, 1.38]
3 Depression severity 1 377 Mean Difference (IV, Random, 95% CI) 0.40 [-0.97, 1.77]
4 Health-related quality of life 1 347 Mean Difference (IV, Random, 95% CI) -4.30 [-7.31, -1.29]
5 Dropout due to any type of adverse
event
1 386 Odds Ratio (M-H, Random, 95% CI) 1.99 [0.60, 6.65]
 
 
Analysis 7.1.   Comparison 7 Imipramine (TCA) versus sertraline (SSRI), Outcome 1 Relapse/recurrence.
Study or subgroup Imipramine Sertraline Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Koran 2001 33/146 41/230 100% 1.27[0.84,1.91]
   
Total (95% CI) 146 230 100% 1.27[0.84,1.91]
Total events: 33 (Imipramine), 41 (Sertraline)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.14(P=0.25)  
Favours imipramine 1000.01 100.1 1 Favours sertraline
 
 
Analysis 7.2.   Comparison 7 Imipramine (TCA) versus sertraline (SSRI), Outcome 2 Dropout due to any reason.
Study or subgroup Imipramine Sertraline Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Koran 2001 18/147 36/239 100% 0.81[0.48,1.38]
   
Total (95% CI) 147 239 100% 0.81[0.48,1.38]
Total events: 18 (Imipramine), 36 (Sertraline)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.77(P=0.44)  
Favours imipramine 1000.01 100.1 1 Favours sertraline
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Analysis 7.3.   Comparison 7 Imipramine (TCA) versus sertraline (SSRI), Outcome 3 Depression severity.
Study or subgroup Imipramine Sertraline Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Koran 2001 146 8.1 (7.1) 231 7.7 (5.8) 100% 0.4[-0.97,1.77]
   
Total *** 146   231   100% 0.4[-0.97,1.77]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
Favours imipramine 10050-100 -50 0 Favours sertraline
 
 
Analysis 7.4.   Comparison 7 Imipramine (TCA) versus sertraline (SSRI), Outcome 4 Health-related quality of life.
Study or subgroup Imipramine Sertraline Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Koran 2001 136 70.9 (15) 211 75.2 (12.2) 100% -4.3[-7.31,-1.29]
   
Total *** 136   211   100% -4.3[-7.31,-1.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.8(P=0.01)  
Favours sertraline 10050-100 -50 0 Favours imipramine
 
 
Analysis 7.5.   Comparison 7 Imipramine (TCA) versus sertraline
(SSRI), Outcome 5 Dropout due to any type of adverse event.
Study or subgroup Imipramine Sertraline Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Koran 2001 6/147 5/239 100% 1.99[0.6,6.65]
   
Total (95% CI) 147 239 100% 1.99[0.6,6.65]
Total events: 6 (Imipramine), 5 (Sertraline)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.12(P=0.26)  
Favours imipramine 1000.01 100.1 1 Favours sertraline
 
 




















NRCT Chronic major depressive disorder, double de-
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Table 1.   Overview of included studies 
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Table 1.   Overview of included studies  (Continued)
*These groups are partially overlapping (see above).






Rating Explanation of judgement Possible ratings
Bias due to con-
founding
5 No information how participants were allocated to
groups in the acute treatment.
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical





2 Different length of drugs and procedures during acute
treatment (participants of 3 protocols were included for
analyses of continuation treatment).
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical
risk, 5 = no information
Table 2.   Risk of bias (non-randomized trials) – Kocsis 1995 
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1 Intervention was well defined: IMI and DMI were contin-
ued on an open basis at the same final dose achieved
during the acute phase.
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical
risk, 5 = no information




1 No indication for departures from intended interven-
tions, check of plasma levels was performed.
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical
risk, 5 = no information
Bias due to
missing data
2 Proportions of missing participants differed substan-
tially across interventions: 26% in the IMI group and
6% in the DMI group, in the IMI group 4 participants did
not comply with the follow-up assessment, reasons for
dropout were reported; but proportion of dropout due
to dissatisfaction with treatment was similar for IMI and
DMI (7% and 6%).
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical




3 Participants in the IMI protocols were seen and rated
once at week 26 of treatment. Participants on the DMI
protocol were seen and rated every 2 weeks through
week 26. Lack of blinding: participants and raters were
aware of the treatment. (see p. 214)
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical
risk, 5 = no information
Bias in selec-
tion of the re-
ported result
3 Not all predefined outcomes were reported separate-
ly for both groups. Some data were assessed every 2
weeks, these data were not reported. In general, data
were not reported for HAM-D and GAS for the DMI vs IMI.
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical
risk, 5 = no information
Table 2.   Risk of bias (non-randomized trials) – Kocsis 1995  (Continued)






Rating Explanation of judgement Possible ratings
Bias due to con-
founding
1 Randomization before acute phase, exclusion of
cross-over participants.
Code 1 = low risk, 2 = moderate risk, 3 =






1 All eligible participants were included, cross-over
participants were excluded; acute phase treat-
ment had the same length and measurement
times for all groups.
Code 1 = low risk, 2 = moderate risk, 3 =





1 Intervention status was well described (planned
and actual dose of medication as well as number
of CBASP sessions).
Code 1 = low risk, 2 = moderate risk, 3 =
serious risk, 4 = critical risk, 5 = no infor-
mation




1 Medication doses as well as number of CBASP
sessions were within the planned range.
Code 1 = low risk, 2 = moderate risk, 3 =
serious risk, 4 = critical risk, 5 = no infor-
mation
Table 3.   Risk of bias (non-randomized trials) – Kocsis 2003 
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Bias due to
missing data
1 Number of missing data was low and comparable
in all groups (2–3%).
Code 1 = low risk, 2 = moderate risk, 3 =





1 Methods of outcome assessment were compara-
ble across intervention groups. Quote: "Trained
independent evaluators unaware of treatment
assignment completed the HAM-D-24 at each as-
sessment visit." (p. 77), no means and standard
deviations reported, unclear if other subscales
were evaluated.
Code 1 = low risk, 2 = moderate risk, 3 =
serious risk, 4 = critical risk, 5 = no infor-
mation
Bias in selec-
tion of the re-
ported result
2 No study protocol existed, but all measures men-
tioned in the methods section were reported in
the outcome section.
Code 1 = low risk, 2 = moderate risk, 3 =
serious risk, 4 = critical risk, 5 = no infor-
mation
Table 3.   Risk of bias (non-randomized trials) – Kocsis 2003  (Continued)






Rating Explanation of judgement Possible ratings
Bias due to con-
founding
1 Randomization before acute phase. Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical





1 All possible participants were included (direct and cross-
over). All measures existing from the beginning of the inter-
vention. The study flow was clearly described since acute
treatment.
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical




1 Intervention status is well defined (dose ranges are de-
scribed in section 2.3 and 3.4).
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical
risk, 5 = no information




1 Assignment to intervention. Quote: "For both treatment
groups, 10% of patients had dose increases aimed at im-
proving outcome" (p. 31); same for both groups with re-
gard to the main outcome; adapting dose is usual practice;
no deviation from intended treatment, they counted the
tablets.
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical
risk, 5 = no information
Bias due to
missing data
1 Quote: "For all patients, including drop outs, pill counts
indicated compliance rates of 88.7% for imipramine and
84.7% for sertraline. No differences were found between
diagnostic groups or between acute and crossover pa-
tients." (p. 31); Proportions of and reasons for missing par-
ticipants were similar across intervention groups; less than
5% dropout for the main outcome; proportions of missing
data were comparable and are addressed in the analyses
with LOCF.
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical




1 Information from Rush et al., 1998 (study protocol): reli-
able ratings (p. 593); quote: "continued on the same dou-
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical
risk, 5 = no information
Table 4.   Risk of bias (non-randomized trials) – Koran 2001 
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ble-blind medication dose for an additional 16 weeks" (p.
593); assessment methods comparable across groups.
Bias in selec-
tion of the re-
ported result
2 Outcomes correspond to the ones named in the protocol,
but protocol just for acute phase; not all measures used
during the acute phase were used in continuation phase.
Code 1 = low risk, 2 = moderate
risk, 3 = serious risk, 4 = critical
risk, 5 = no information
Table 4.   Risk of bias (non-randomized trials) – Koran 2001  (Continued)
LOCF: last observation carried forward.
 
 
A P P E N D I C E S
Appendix 1. CCMD-CTR
Description of the Cochrane Common Mental Disorders Controlled Trials Register (CCMD-CTR)
The Cochrane Common Mental Disorders Group maintains a specialized register of randomized controlled trials (RCT) the CCMD-CTR.
This register contains over 39,000 reference records (reports of RCTs) for depression, anxiety, and other common mental disorders. A
percentage of the reference records have been tagged to 12,500 individual, PICO coded study records (with coding based on the EU-
Psi coding manual). Reports of trials for inclusion in the register are collated from (weekly), generic searches of MEDLINE, Embase, and
PsycINFO, quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), and review specific searches of additional
databases. Reports of trials are also sourced from international trial registries, drug companies, the handsearching of key journals,
conference proceedings, and other (non-Cochrane) systematic reviews and meta-analyses. Details of CCMD's core search strategies can be
found on the Group's website, with an example of the core MEDLINE search displayed in below.
In 2016 the Group's Specialized Register (CCMD-CTR) became out of date with the Editorial Group's move from Bristol to York.
The search strategy listed below is the weekly Ovid MEDLINE search which was used to inform the Group's specialized register (to
June 2016). It is based on a list of terms for all conditions within the scope of the Cochrane Common Mental Disorders Group plus
a sensitive RCT filter.
1. [MeSH Headings]:
eating disorders/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or female athlete triad syndrome/ or pica/
or hyperphagia/ or bulimia/ or self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide, attempted/ or
mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or depression,
postpartum/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or seasonal affective
disorder/ or neurotic disorders/ or depression/ or adjustment disorders/ or exp antidepressive agents/ or anxiety disorders/ or
agoraphobia/ or neurocirculatory asthenia/ or obsessive-compulsive disorder/ or obsessive hoarding/ or panic disorder/ or phobic
disorders/ or stress disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/
or anxiety/ or anxiety, castration/ or koro/ or anxiety, separation/ or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body
dysmorphic disorders/ or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ or munchausen syndrome by proxy/ or
munchausen syndrome/ or fatigue syndrome, chronic/ or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse
control disorders/ or firesetting behavior/ or gambling/ or trichotillomania/ or stress, psychological/ or burnout, professional/ or sexual
dysfunctions, psychological/ or vaginismus/ or Anhedonia/ or Affective Symptoms/ or *Mental Disorders/
2. [Title/ Author Keywords]:
(eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid* or
mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or cyclothymic* or
depression or depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or agoraphobia
or obsess* or compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform or somati#ation or medical*
unexplained or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or munchausen or chronic fatigue*
or gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or mental disorder* or mental health).ti,kf.
3. [RCT filter]:
(controlled clinical trial.pt. or randomised controlled trial.pt. or (randomi#ed or randomi#ation).ab,ti. or randomly.ab. or (random* adj3
(administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number* or place*
or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial* or study or
studies)).ab,ti. or ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. or clinical trial, phase ii/ or clinical trial, phase
iii/ or clinical trial, phase iv/ or randomised controlled trial/ or pragmatic clinical trial/ or (quasi adj (experimental or random*)).ti,ab. or
((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.)
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4. (1 and 2 and 3)
Records were screened for reports of RCTs within the scope of the Cochrane Common Mental Disorders Group. Secondary reports of RCTs
were tagged to the appropriate study record.
Appendix 2. Other database searches
Ovid PsycINFO (all years to 11 December 2015).





4. MAJOR DEPRESSION/ and ("CHRONICITY (Disorders)"/ or CHRONIC ILLNESS/)
5. (dysthymi*).ti,ab,id.
6. RECURRENT DEPRESSION/
7. (depress* adj2 recurr*).ti,ab,id.




11. (maintenance or maintained).ti,ab,id.
12. continuation.ti,ab,id.





17. exp EXPERIMENTAL DESIGN/
18. TREATMENT EFFECTIVENESS EVALUATION/
19. MENTAL HEALTH PROGRAM EVALUATION/
20. (empirical study or longitudinal study or prospective study or quantitative study).md.
21. "2000".md. [treatment outcome/clinical study]
22. RETROSPECTIVE STUDIES/
23. EVIDENCE BASED PRACTICE/
24. (study or trial or treatment* or intervention or therap* or psychotherap*).ti.
25. (control* adj3 (group*1 or study or trial)).ti,ab,id.
26. (waitlist* or wait list* or treatment* as usual or TAU or care as usual or standard care or standard treatment*).ti,ab,id.
27. placebo.ti,ab,id.
28. PLACEBO/
29. (RCT or random*).ti,ab,id.
30. (crossover* or cross over*).ti,ab,id.
31. (quasi experimental).ti,ab,id.
32. (longitudinal or cohort).ti,ab,id.
33. (case adj (control or report or series)).ti,ab,id.
34. (cross-sectional).ti,ab,id.
35. (experimental or quantitative or pilot).ti,ab,id.
36. or/17-35
37. (9 and 16 and 36)
[Psychotherapies]
38. exp PSYCHOTHERAPY/
39. exp PSYCHOTHERAPEUTIC TECHNIQUES/
40. exp COGNITIVE TECHNIQUES/
41. exp COUNSELING/
42. 3300.cc. [Classification Code: Health & Mental Health Treatment & Prevention]
43. 3310.cc. [Classification Code: Psychotherapy & Psychotherapeutic Counseling]
44. 3311.cc. [Classification Code: Cognitive Therapies]
45. 3312.cc. [Classification Code: Behavior Therapy & Behavior Modification]
46. 3313.cc. [Classification Code: Group & Family Therapy]
47. 3314.cc. [Classification Code: Interpersonal & Client Centered & Humanistic Therapy]
48. 3315.cc. [Classification Code: Psychoanalytic Therapy]
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49. (CBT or c-CBT or iCBT or coping skills or counsel?ing or mindfulness or psychoanal* or psychotherap* or rehabilitat*).ti,ab,id.
50. ((psychologic* or psychodynamic or behavio?r or cognitive) adj3 (intervent* or therap* or treat* or manag*)).ti,ab,id.
51. (Abreaction or Acting Out or Adlerian or Adolescent Psychotherap* or Age Regression or Analytical Psychotherap* or Anger Control
or Anger Management or Art Therap* or Assertive* Training or Autogenic Training or Autosuggestion or Aversion Therap* or Balint Group
or Behavio?r Contracting or Behavio?r Modification or Behavio?r Therap* or Bibliotherap* or Biofeedback or Body Psychotherap* or Brief
Psychotherap* or Caregiver Support or Child Psychotherap* or Client Cent* Therapy or Cognitive Behavio?r Therap* or Cognitive Behavio?
ral Stress Management or Cognitive Rehabilitation or Cognitive Restructuring or Cognitive Therap* or Colo?r Therap* or Conjoint Therap*
or Contingency Management or Conversion Therap* or Conversational Therap* or Countertransference or Couples Therap* or Covert
Sensitization or Crisis Intervention).ti,ab,id,de.
52. (Dance Therap* or Dialectical Behavio?r Therap* or (Dream* adj3 Analys*) or Eclectic Psychotherap* or Eclectic Therap* or Emotion*
Focus* Therap* or Emotional Freedom Technique or Encounter Group Therap* or Existential Therap* or Experiential Psychotherap* or
Exposure Therap* or Expressive Psychotherap* or Eye Movement Desensiti#ation or Family Therap* or Free Association or Geriatric
Psychotherap* or Gestalt Therap* or Griefwork or Group Psychotherap* or Group Therap* or Guided Image* or Holistic Psychotherap* or
Humanistic Psychotherap* or Hypnosis or Hypnotherapy or Hypnoti#zability or Implosive Therap* or Individual Psychotherap* or Insight
Therap* or Integrative Psychotherap* or Integrative Therap* or Interpersonal Psychotherap*).ti,ab,id,de.
53. (Logotherap* or Marathon Group Therap* or Marital Therap* or Meditation or Mental Healing or Metacognitive Therap* or Milieu Therap*
or Mind train* or Morita Therap* or Music Therap* or Narrative Therap* or Nondirective Therap* or Personal Construct Therap* or Person
Cent* Therap* or Persuasion Therap* or Pet Therap* or Play Therap* or Primal Therap* or Problem Solving Therap* or Psychoanalysis
or Psychoanalytic Therap* or Psychodrama or Psychodynamic Psychotherapy or Psychotherapeutic Counsel* or Psychotherapeutic
Processes or Psychotherapeutic Training or (Psychotherap* adj3 Rational-Emotive)) .ti,ab,id,de.
54. (Rational Emotive Behavio?r Therap* or Reality Therap* or Reciprocal Inhibition Therap* or Relationship Therap* or Relaxation Stress
Management or Relaxation Technique* or Relaxation Therap* or Relaxation Training or Reminiscence Therap* or Role Playing or Self
Analys* or Self Esteem Building or Sensitivity Training Group* or Sex Therap* or Sleep Phase Chronotherap* or Socioenvironmental Therap*
or Sociotherap* or Solution Focused Therap* or Support Group* or (Support adj3 Psycho*) or Systematic Desensiti#ation or Therapeutic
Communit* or Transactional Analysis or Validation Therap*).ti,ab,id,de.
55. or/38-54
[Antidepressants]
56. PSYCHOPHARMACOLOGY/ or NEUROPSYCHOPHARMACOLOGY/
57. 3340.cc. [Classification Code: Clinical Psychopharmacology]
58. exp ANTIDEPRESSANT DRUGS/
59. NEUROTRANSMITTER UPTAKE INHIBITORS/ or exp SEROTONIN NOREPINEPHERINE REUPTAKE INHIBITORS/ or exp SEROTONIN
REUPTAKE INHIBITORS/
60. exp MONOAMINE OXIDASE INHIBITORS/
61. exp TRICYCLIC ANTIDEPRESSANT DRUGS/
62. (antidepress* or anti depress* or MAOI* or monoamine oxidase inhibit* or ((serotonin or norepinephrine or noradrenaline or nor
epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic
or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*).ti,ab,id,de.
63. (Agomelatine or Alnespirone or Amoxapine or Amfebutamone or Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or
Amoxapine or (Atomoxetine or Tomoxetine) or Benactyzine or Brofaromine or Bupropion or Butriptylin* or Cianopramine or Cilobamine or
Citalopram or (Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or Clovoxamine or (CX157 or Tyrima)
or Dapoxetine or Deanol or Dibenzepin* or Demexiptilin* or Deprenyl or Desipramine or Desvenlafaxine or Dibenzepin or Dimetacrin* or
(Dosulepin or Dothiepin) or Doxepin or Duloxetine or DVS-233 or Enilospirone or Eptapirone or Escitalopram or Etoperidone or Femoxetine
or Fluotracen or Fluoxetine or Fluparoxan or Furazolidone or Fluvoxamine or Harmaline or Harmine or Hyperforin or Hypericum or
John* Wort or Idazoxan or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Imipraminoxide or Isocarboxazid* or Lesopitron or
Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 or Vortioxetine) or Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine
or Melitracen or Metapramine or Mianserin or Milnacipran or Minaprine or Mirtazapine or Moclobemide or Nefazodone or Nialamide or
Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptyline or Noxiptilin* or Opipramol or Oxaflozane or Paroxetine or Phenelzine
or Pheniprazine or Pipofezin* or Pirandamine or Piribedil or Pirlindole or Pivagabine or Pizotyline or Propizepine or (Protriptylin* or
Pertofrane) or Quinupramine or Quipazine or Reboxetine or Ritanserin or Rolipram or Scopolamine or Selegiline or Sertraline or (Setiptiline
or Teciptiline) or Tandospirone or Tetrindole or Thiazesim or Thozalinone or Tianeptin* or Toloxatone or Tranylcypromine or Trazodone or
Trimipramine or 5-Hydroxytryptophan or 5-HT or Tryptophan or Hydroxytryptophan or Venlafaxine or Viloxazine or Vilazodone or Viqualine
or Zalospirone or Zimeldine or (Alaproclate or Caroxazone or Diclofensine or Fenfluramine)) .ti,ab,id,de.
64. or/56-63
[Mood Stabilisers or Antipsychotics]
65. MOOD STABILIZERS/
66. exp ANTICONVULSIVE DRUGS/
67. exp NEUROLEPTIC DRUGS/
68. ((mood stabili?er*1 or lithium or eslicarbazepine or licarbazepine or valnoctamide or carbamazepine or valproate or valproic acid
or divalpro* or ziprasidone or gabapentin or lamotrigine or topiramate) or (antipsychotic*1 or amisulpride or aripiprazole or asenapine
or cariprazine or clozapine or haloperidol or iloperidone or lurasidone or olanzapine or quetiapin* or paliperidone or prosulpride or
risperidone)).ti,ab,id,de.
69. or/65-68
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70. (9 and (55 or 64 or 69) and 36)
71. 37 or 68
Validated Ovid cross-search-1 (all years to 4 October 2016 and updated 28 Sepetmber 2018)
PsycINFO 1987 -, Embase 1974 -, MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R) 1946 -
1. MAINTENANCE THERAPY/
2. (continuation or maintenance).ti.
3. ((continuation or maintenance) adj2 (efficacy or effectiveness or medicat* or pharmacotherap* or phase or study or therap* or
psychotherap* or treatment*)).ti,ab,id,kf,kw.




8. DYSTHYMIC DISORDER/ or DYSTHYMIA/
9. dysthymi*.ti,ab,id,kf,kw.
10. MAJOR DEPRESSION/ or DEPRESSIVE DISORDER/ or DEPRESSIVE DISORDER, MAJOR/
11. "CHRONICITY (DISORDERS)"/ or CHRONIC ILLNESS/ or CHRONIC DISEASE/ or RECURRENCE/ or RECURRENT DISEASE/ or RECURRENCE
RISK/ or REMISSION/
12. (10 and 11)
13. RECURRENT DEPRESSION/
14. (depress* adj2 recurr*).ti,ab,id,kf,kw.
15. persistent depressive disorder.ti,ab,id,kf,kw.
16. (6 or 7 or 8 or 9 or 12 or 13 or 14 or 15)
17. (5 and 16)
[Key: ti = title; ab = abstract; kf = author keyword MEDLINE; kw = author keyword Embase; id = key concepts PsycINFO]
Cochrane Central Register of Controlled Trials (CENTRAL) Issue 9, 2016 and Issue 9, 2018
#1 (continuation or maintenance):ti
#2 ((continuation or maintenance) near/3 (efficacy or effectiveness or medicat* or pharmacotherap* or phase or study or therap* or
psychotherap* or treatment*))
#3 ((continu* or maint*) next (medicat* or pharmacotherap* or therap* or psychotherap* or treatment*))
#4 (#1 or #2 or #3)
#5 "chronic* depress*"
#6 "doubl* depress*"
#7 MeSH descriptor: [DYSTHYMIC DISORDER] this term only
#8 dysthymi*
#9 MeSH descriptor: [DEPRESSIVE DISORDER] this term only
#10 MeSH descriptor: [DEPRESSIVE DISORDER, MAJOR] this term only
#11 MeSH descriptor: [CHRONIC DISEASE] explode all trees
#12 MeSH descriptor: [RECURRENCER] this term only
#13 (#9 or #10) and (#11 or #12)
#14 (depress* near/3 recurr*)
#15 (persistent next depress*)
#16 (#5 or #6 or #7 or #8 or #13 or #14 or #15)
#17 (#4 and #16)
The 2016 search identified 929 new references.
Update search (28 September 2018)
The following search string was appended to the update search of both Ovid and the Cochrane Library Trials database (all years to date)
(with appropriate syntax amendments for CENTRAL):
((longterm or long term or continu* or maintain*) and ((prevent* or probability or reduc* or time to or decreas* or risk?) adj2
recurrence)).ti,ab,id,kf,kw. AND ((dysthymi*.ti. or (depress*.ti. and (chronic or persist*).mp.) or double depression.ti,ab,id,kf,kw.))
The 2018 search identified 141 new references.
H I S T O R Y
Protocol first published: Issue 11, 2017
Review first published: Issue 5, 2019
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Date Event Description
8 February 2019 Feedback has been incorporated feedback of sign-off editor had been incorporated
 
C O N T R I B U T I O N S   O F   A U T H O R S
AJ, LK and MH applied for funding.
SL, KM, AJ, RM, BW, MH, and LK developed the protocol.
KM, SL, AJ and RM screened the literature and extracted the data.
KM, SL, RM and LK conducted the analyses.
KM, SL and RM wrote the first version of the manuscript.
D E C L A R A T I O N S   O F   I N T E R E S T
AJ, LK, and MH co-ordinated the update of the S3 Guideline/National Clinical Practice Guideline "Unipolar Depression" (DGPPN 2015). The
expert association DGPPN (editor of the S3 Guideline) provided financial support for the preparation of the Guideline Update to the co-
ordinators' institution (Department of Medical Psychology, University Medical Center Hamburg-Eppendorf).
KM, BW, AJ, LK, RM, and MH report participating in publicly funded investigator-initiated primary studies and systematic reviews of
interventions for people with depression.
KM, BW, AJ, RM, MH, and SL have had formal training in behavioural psychotherapy.
S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support supplied
External sources
• German Ministry of Education and Research, Germany.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We replaced the term CCT (clinical controlled trial) by the term NRCT (non-randomized controlled trial), and updated the name of the tool
for analyzing NRCTs to "ROBINS-I tool" (previously called ACROBAT-NRSI).
From the seven planned comparisons, we were able to analyse five comparisons. None of the studies provided data for the following two
comparisons: pharmacological continuation and maintenance therapies versus treatment as usual (TAU); and psychological continuation
and maintenance therapies versus treatment as usual (TAU). We included an additional comparison as two studies provided data:
pharmacological continuation and maintenance therapies versus other pharmacological continuation and maintenance therapies (post
hoc) medications.
We provided 'Summary of findings' tables for only one comparison (pharmacotherapy versus placebo) as there were few data for the other
comparisons.
In the original protocol, we planned analysis of follow-up data that ranged between six and 18 months aRer the end of the intervention
with a preference for the time that was closest to one year aRer the end of the intervention. In this review, only one study provided follow-
up data, with time point at 12 weeks aRer the end of the intervention, which is not in the predefined range of six to 18 months aRer the end
of the intervention. As just one study provided follow-up data, we still included these data into this review.
Due to the small number of included studies, subgroup and meta-regression analyses were not performed. Not all predefined sensitivity
analyses could be performed due to lack of variation concerning risk of bias in some domains.
To test for publication bias, Eggers' test could not be applied, as it requires a minimum 10 studies per comparison.
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults (Review)









Cochrane Database of Systematic Reviews
We planned to include all participants allocated to the respective study arm in the primary outcome analyses. However, when data on
relapse/recurrence were missing for some participants, we used the data provided instead of calculating relapse/recurrence rates ourselves
since a classification of all participants without available data as 'relapsed/recurred' probably results in a biased estimate. Continuous data
suitable for a calculation of relapse/recurrence rates were not available throughout. Certainly, the percentage of missing data concerning
this outcome was low: in five studies relapse/recurrence rates were provided for the whole sample, in two studies this outcome was
not addressed and in three studies the amount of missing data ranged between 2% and 10%. Data on the primary acceptance outcome
(dropout any) were provided for the whole intention-to-treat sample.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Antidepressive Agents  [*therapeutic use];  Depressive Disorder, Major  [*therapy];  Psychotherapy  [*methods];  Treatment Outcome
MeSH check words
Humans
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